


Post-transcriptional regulation of antiviral gene expression by *N*6-methyladenosine

Graphical Abstract



Authors

Michael J. McFadden,
Alexa B.R. McIntyre,
Haralambos Mourelatos, ...,
Blerta Xhemalçe, Christopher E. Mason,
Stacy M. Horner

Correspondence

stacy.horner@duke.edu

In brief

McFadden et al. report that the transcripts of many interferon-stimulated genes (ISGs), which encode antiviral proteins, are m⁶A-modified. m⁶A promotes the translation of certain ISGs, enhancing the antiviral effects of interferon. This study adds to our understanding of the functions of m⁶A at the virus-host interface.

Highlights

- During the type I IFN response, many IFN-stimulated genes (ISGs) are modified by m⁶A
- m⁶A promotes the expression of a subset of these ISGs by enhancing their translation
- m⁶A augments the antiviral effects of the type I interferon response



Article

Post-transcriptional regulation of antiviral gene expression by *N*6-methyladenosine

Michael J. McFadden,¹ Alexa B.R. McIntyre,^{2,3,9,11} Haralambos Mourelatos,^{4,9} Nathan S. Abell,^{5,6,9} Nandan S. Gokhale,^{1,12} Hélène Ipas,⁵ Blerta Xhemalçe,^{5,10} Christopher E. Mason,^{2,3,7,10} and Stacy M. Horner^{1,8,13,*}

¹Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA

²Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY 10021, USA

³Tri-Institutional Program in Computational Biology and Medicine, New York, NY 10021, USA

⁴Weill Cornell/Rockefeller/Memorial Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY 10021, USA

⁵Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA

⁶Department of Genetics, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305-5324, USA

⁷The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA

⁸Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA

⁹These authors contributed equally

¹⁰These authors contributed equally

¹¹Present address: Department of Molecular Life Sciences, University of Zurich, Zurich, Switzerland

¹²Present address: Department of Immunology, University of Washington, Seattle, WA 98109, USA

¹³Lead contact

*Correspondence: stacy.horner@duke.edu

<https://doi.org/10.1016/j.celrep.2021.108798>

SUMMARY


Type I interferons (IFNs) induce hundreds of IFN-stimulated genes (ISGs) in response to viral infection. Induction of these ISGs must be regulated for an efficient and controlled antiviral response, but post-transcriptional controls of these genes have not been well defined. Here, we identify a role for the RNA base modification *N*6-methyladenosine (*m*⁶A) in the regulation of ISGs. Using ribosome profiling and quantitative mass spectrometry, coupled with *m*⁶A-immunoprecipitation and sequencing, we identify a subset of ISGs, including *IFITM1*, whose translation is enhanced by *m*⁶A and the *m*⁶A methyltransferase proteins METTL3 and METTL14. We further determine that the *m*⁶A reader YTHDF1 increases the expression of *IFITM1* in an *m*⁶A-binding-dependent manner. Importantly, we find that the *m*⁶A methyltransferase complex promotes the antiviral activity of type I IFN. Thus, these studies identify *m*⁶A as having a role in post-transcriptional control of ISG translation during the type I IFN response for antiviral restriction.

INTRODUCTION

The interferon (IFN) family cytokines are potent inhibitors of viral infection that induce hundreds of IFN-stimulated genes (ISGs), of which many have antiviral activity (González-Navajas et al., 2012; Schoggins and Rice, 2011). Type I IFNs (IFN- α and IFN- β) are produced in response to viral infection, and they activate autocrine and paracrine signaling responses through the JAK-STAT pathway (Stark and Darnell, 2012). Specifically, type I IFNs bind to a dimeric receptor (IFNAR) composed of two subunits, namely, IFNAR1 and IFNAR2. IFNAR engagement then activates the Janus kinases JAK1 and TYK2, which phosphorylate the transcription factors STAT1 and STAT2, inducing their hetero-dimerization and interaction with IRF9, to form the ISGF3 transcription factor complex. ISGF3 then translocates into the nucleus, where it binds to IFN-stimulated response elements within the promoters of ISGs to elicit their transcriptional activation (Stark and Darnell, 2012). Many of these ISGs encode antiviral effector proteins

that inhibit multiple stages of viral replication and thus establish an early defense against viral replication (Schoggins, 2019). Dysregulation of type I IFNs can lead to viral susceptibility or autoimmune disease (Banchereau and Pascual, 2006; Teijaro, 2016), demonstrating the importance of tight regulatory control of both IFN activation and the IFN response. Indeed, both activation and suppression of the type I IFN response are coordinated at multiple levels, such as by epigenetic modifiers (Fang et al., 2012; Huang et al., 2002; Liu et al., 2002) or by post-transcriptional mechanisms including microRNA (miRNA) regulation and alternative splicing (Forster et al., 2015; West et al., 2019). However, our overall understanding of post-transcriptional regulation of ISG expression is still emerging. Additionally, although a number of studies have identified subsets of ISGs that have unique transcriptional regulators, other mechanisms that govern the regulation of subclasses of ISGs have not been well characterized (Froggatt et al., 2019; Perwitasari et al., 2011; Seifert et al., 2019).





(legend on next page)

The RNA base modification *N*6-methyladenosine (m^6A) is deposited on RNA by a methyltransferase complex of METTL3 and METTL14 (METTL3/14), among other proteins (Liu et al., 2014). m^6A coordinates biological processes through various effects on modified mRNAs (Meyer and Jaffrey, 2017; Shi et al., 2019), including increased mRNA turnover and translation, as well as other processes. These effects are mediated by m^6A reader proteins, such as YTHDF proteins (Liu et al., 2019a; Wang et al., 2014, 2015). Specifically, YTHDF1 increases translation (Wang et al., 2015), YTHDF2 mediates mRNA degradation (Wang et al., 2014), and YTHDF3 cooperatively enhances both of these processes (Shi et al., 2017), although in some cases these proteins may have overlapping functions (Zaccara and Jaffrey, 2020). Through the actions of m^6A reader proteins, m^6A can regulate infection by many viruses through modulation of both viral and host transcripts (Williams et al., 2019). We recently profiled changes to the m^6A landscape of host mRNAs during *Flaviviridae* infection and identified both proviral and antiviral transcripts regulated by m^6A during infection (Gokhale et al., 2019). Others have found that m^6A prevents RNA sensing or regulates the expression of signaling molecules involved in the production of cytokines such as type I IFNs (Chen et al., 2019; Durbin et al., 2016; Feng et al., 2018; Karikó et al., 2005; Lu et al., 2020; Zheng et al., 2017) and that m^6A can destabilize the *IFNB1* transcript, thereby directly regulating the production of IFN- β (Rubio et al., 2018; Winkler et al., 2019). Therefore, m^6A plays important roles in viral infection and the antiviral response (Zhang et al., 2019a); however, a role for m^6A in the response to type I IFN and the production of ISGs has not been described.

Here, we mapped m^6A in the IFN- β -induced transcriptome and identified many ISGs that are m^6A -modified. We found that METTL3/14 and m^6A promote the translation of certain m^6A -modified ISGs, in part through interactions between the transcripts of m^6A -modified ISGs and the m^6A reader protein YTHDF1. Importantly, we found that METTL3/14 and m^6A -mediated enhancement of ISG expression promotes the antiviral effects of the IFN response, as METTL3/14 perturbation affected the replication of vesicular stomatitis virus (VSV) in IFN- β -primed cells. Together, these results establish m^6A as a post-transcriptional regulator of ISGs for an effective cellular antiviral response.

RESULTS

METTL3/14 regulates the translation of certain ISGs

IFN- β induces the transcription of ISGs to shape the innate response to viral infection (Schoggins and Rice, 2011). To

investigate whether m^6A regulates the type I IFN response, we measured the IFN- β -induced expression of several ISGs with known antiviral functions (Schoggins, 2014) following depletion of the m^6A methyltransferase complex METTL3/14 in Huh7 cells. The IFN- β -induced protein expression of the ISGs IFITM1 and MX1, but not ISG15 and EIF2AK2 (also called PKR), was reduced following depletion of METTL3/14 (Figure 1A; see STAR methods for IFITM1 antibody specificity). Similar results were also seen in A549 cells, primary neonatal human dermal fibroblasts (NHDFs), and also at multiple time points (8 h, 16 h, and 24 h) after IFN- β in Huh7 cells (Figures S1A–S1C); however, we note MX1 protein levels were not as strongly affected in A549 and NHDF cells as in Huh7 cells. Conversely, overexpression of METTL3/14 increased the abundance of IFITM1 and MX1, but not ISG15 and EIF2AK2, in response to IFN- β in Huh7 cells (Figure 1B). Importantly, the METTL3/14-regulated ISGs IFITM1 and MX1 were not expressed without IFN- β , suggesting that any confounding effects of METTL3/14 perturbation on endogenous IFN- β production are negligible (Figures 1A and 1B).

METTL3/14 regulates many aspects of mRNA metabolism (Liu et al., 2019a). To determine how METTL3/14 regulates the protein abundance of certain ISGs, we first tested whether METTL3/14 depletion led to a decrease in ISG mRNA in response to IFN- β . We measured the induction of ISG mRNA following IFN- β -induction over a time course by using qRT-PCR (Figure S1D). Neither the mRNA abundance nor the induction kinetics of the METTL3/14-regulated ISGs *IFITM1* and *MX1* were affected by METTL3/14 depletion. The mRNA levels of the non-METTL3/14-regulated ISG *EIF2AK2* was unaffected, whereas *ISG15* mRNA was increased (Figure S1D). Thus, the mRNA abundance of *IFITM1* and *MX1* does not underlie the observed differences in protein levels, suggesting that neither the transcription nor the mRNA stability of these ISGs are regulated by METTL3/14 (Figure S1D). Furthermore, using RNA sequencing (RNA-seq) following IFN- β treatment, we noted little effect of METTL3/14 depletion on the mRNA abundance of a defined set of core ISGs (Shaw et al., 2017) (Figure S1E) or expressed ISGs more broadly (Data S1). These data agree with a previous report that found that collective ISG RNA stability is unaffected by METTL3 depletion (Winkler et al., 2019).

As METTL3/14 depletion resulted in less IFITM1 and MX1 protein without affecting their transcript levels, we tested if METTL3/14 regulates their protein stability. However, despite the expected decrease in IFITM1 and MX1 protein after METTL3/14 depletion and IFN induction, the rate of their protein decay was

Figure 1. METTL3/14 regulates translation of certain ISGs

(A and B) Immunoblot analysis of extracts from Huh7 cells transfected with siRNAs to METTL3/14 (M3/14) or control (CTRL) (A) or stably overexpressing FLAG-METTL14 (M3/14^{OE}; top arrow denotes FLAG-METTL14; bottom arrow denotes endogenous METTL14) (B) prior to mock or IFN- β (24 h) treatment. Relative ISG expression from 4 replicates of (A) and (B) is quantified below relative to non-targeting control (siCTRL) + IFN- β (A) or WT + IFN- β (B).

(C–E) qRT-PCR analysis of the relative percentage of *IFITM1* (C), *MX1* (D), and *GAPDH* (E) mRNA across 24 sucrose gradient fractions isolated from extracts of IFN- β -treated (6 h) Huh7 cells treated with CTRL or METTL3/14 siRNA. The uninitiated (free, 40S, and 60S subunits), initiated (80S), low- or high-molecular-weight polysomes are noted. Graphs on the right show the percentages of mRNAs in combined fractions for *IFITM1*, *MX1*, or *GAPDH*. Percentages from fractions were added to yield the total percentage in each category.

Values are the mean \pm SEM of 4 biological replicates (A and B), the mean \pm SD of 3 technical replicates, representative of 3 experiments (C–E, left graphs), and the mean \pm SEM of 3 biological replicates (C–E, right graphs). * p < 0.05, ** p < 0.01, *** p < 0.005 by unpaired Student's *t* test (A and B), and 2-way ANOVA with Sidak's multiple comparisons test (C–E). ns, not significant.

See also Figures S1 and S2.




Figure 2. METTL3/14-regulated ISGs are modified by m⁶A

(A) Metagen plot of predicted m⁶A distribution across the transcriptome following IFN-β treatment (8 h), with relative positions of DRACH motif sites under statistically significant peaks plotted, as well as the most highly enriched motif under peaks.

(B) The percent of genes modified by m⁶A in the expressed transcriptome, genes with mRNA induction ≥4-fold in response to IFN-β treatment (ISGs), a group of core ISGs conserved in vertebrate species (Shaw et al., 2017), or a subset of these core ISGs with antiviral functions (Shaw et al., 2017).

(C-F) Read coverage plots of MeRIP-seq (red) and input (black) reads in *IFITM1* (C), *MX1* (D), *ISG15* (E), and *EIF2AK2* (F) transcripts. Variance between biological replicates is represented by red and black shading around read coverage. Gray shading represents coding sequence; yellow shading represents m⁶A peaks called by MeTDiff (Cui et al., 2018) and meRIPper (https://sourceforge.net/projects/meripper/) software. All analyses were performed on 3 biological replicates.

See also Figure S3.

not affected following cycloheximide treatment, which blocks protein synthesis (Figures S2A and S2B). Additionally, as both METTL3/14 and m⁶A can promote the nuclear export of certain mRNAs (Lesbirel and Wilson, 2019), we also tested whether the nuclear export of select ISGs was altered by METTL3/14 depletion. However, after IFN stimulation, METTL3/14 depletion did not alter the nuclear-cytoplasmic ratio of the METTL3/14-regulated ISGs *IFITM1* and *MX1*, the non-regulated ISGs *ISG15* and *EIF2AK2*, a non-methylated control *HPRT1* (Wang et al., 2014), or the nuclear-localized control *MALAT1* (Figure S2C). Therefore, METTL3/14 did not detectably regulate the nuclear export or protein stability of these ISGs in Huh7 cells.

To test if METTL3/14 regulates *IFITM1* translation, we measured its polysome occupancy in control cells or in those depleted of METTL3/14 post-IFN-β. METTL3/14 depletion did not change overall polysome density, as observed by the similar relative absorption across fractions (Figure S2D). However, METTL3/14 depletion did result in lower levels of *IFITM1* mRNA in the 80S fractions and a shift from the heavy to the light polysome fractions (Figure 1C), indicating impaired translation of *IFITM1* following METTL3/14 depletion. A similar, yet less pronounced, shift was observed for *MX1* (Figure 1D) but not for the housekeeping control gene *GAPDH* (Figure 1E). These results indicate that METTL3/14 regulates the translation of certain ISGs, such as *IFITM1* and *MX1*.

METTL3/14-regulated ISGs are modified by m⁶A

To determine whether the METTL3/14-regulated ISGs *IFITM1* and *MX1*, as well as other ISGs, are m⁶A-modified, we mapped m⁶A in the IFN-induced transcriptome in Huh7 cells by using methylated RNA immunoprecipitation and sequencing (MeRIP-seq) (Dominissini et al., 2012; Meyer et al., 2012). After defining the ISGs (Figure S3A; Data S2), we then called peaks in read

coverage post-m⁶A immunoprecipitation compared to input by using the MeTDiff m⁶A peak caller (Cui et al., 2018; Data S2). Peaks across mRNAs were enriched around the end of the coding sequence and the beginning of the 3' UTR, as expected (Dominissini et al., 2012; Meyer et al., 2012; Figure 2A). The most highly enriched RNA sequence motif within peaks was [U/A]GGAC, which matches the known m⁶A motif of DRAC^mC (Dominissini et al., 2012; Meyer et al., 2012; Figure 2A). Approximately 85% percent of ISGs, classified as those upregulated more than 4-fold following IFN, were m⁶A-modified, as compared to 74% percent of the expressed transcriptome of Huh7 cells (mean coverage, ≥10) (Figure 2B). This result was consistent with a previous study that found that ISGs were m⁶A-modified at a similar percentage to the transcriptome (Winkler et al., 2019). The percent of ISGs that are m⁶A-modified was similar among other classes of ISGs, including a "core" class of ISGs that are evolutionarily conserved among vertebrate species and a subset of 14 of these core ISGs with known antiviral functions (Shaw et al., 2017; Figure 2B). Plotting the MeRIP-seq reads relative to the input reads of individual genes can be informative of m⁶A status, as m⁶A peak calling methods have known limitations (McIntyre et al., 2020). Thus, we generated plots for *IFITM1*, *MX1*, *ISG15*, and *EIF2AK2* and used the m⁶A peak callers MeTDiff (Cui et al., 2018) and meRIPper (https://sourceforge.net/projects/meripper/) (Data S2) to reveal that the METTL3/14-regulated genes *IFITM1* and *MX1* had m⁶A peaks (Figures 2C and 2D), whereas *ISG15* and *EIF2AK2* lacked called m⁶A peaks (Figures 2E and 2F). These plots suggested that the 3' UTR of *ISG15* may also contain an m⁶A site (Figure 2E). We then compared the m⁶A status of ISGs from our MeRIP-seq experiment to data from published studies that profiled m⁶A after IFN-inducing treatments, such as double-stranded DNA (dsDNA) (Rubio et al., 2018) or human cytomegalovirus (HCMV)

infection (Winkler et al., 2019; Figure S3B). This comparison showed consistent prediction of m⁶A status for core antiviral ISGs among all three studies (Figure S3B). Indeed, dsDNA treatment potently activates IFN production and elicited m⁶A modification of the same core antiviral ISGs found in our experiment. Infection with HCMV also elicited m⁶A modification of certain ISGs, although fewer peaks were called in these ISGs after HCMV infection than after IFN- β treatment or dsDNA treatment (Figure S3B). We note this virus encodes factors to dampen IFN signaling (Miller et al., 1999); therefore, ISGs are likely not as strongly induced as dsDNA or IFN- β treatment. The presence of m⁶A on many ISGs suggests that m⁶A may regulate the antiviral type I IFN response.

m⁶A modification in the 3' UTR of *IFITM1* enhances its translation

m⁶A enhances the translation of certain mRNAs (Coots et al., 2017; Gokhale et al., 2019; Lin et al., 2016; Mao et al., 2019; Wang et al., 2015). Specifically, the m⁶A reader protein YTHDF1 recognizes m⁶A within 3' UTRs and associates with eukaryotic translation initiation factors such as eIF3 to enhance translation of m⁶A-modified transcripts (Wang et al., 2015). To determine if the translational regulation of ISGs by METTL3/14 is elicited through m⁶A, we used *IFITM1* as a model METTL3/14-regulated ISG. We first determined the effect of METTL3/14 depletion on m⁶A modification of *IFITM1*. MeRIP-qRT-PCR showed that *IFITM1* mRNA was enriched above the m⁶A-negative ISG *EIF2AK2* and a spiked-in m⁶A-negative synthetic RNA, confirming that it contains m⁶A. METTL3/14 depletion reduced the m⁶A enrichment of *IFITM1* mRNA but not of the m⁶A-negative *EIF2AK2* transcript or the m⁶A-negative synthetic RNA (Figures 3A and 3B). These data reveal that *IFITM1* is m⁶A-modified by METTL3/14.

Having confirmed that *IFITM1* is m⁶A-modified, we next generated a luciferase reporter that contains an IFN-stimulated response element (ISRE)-promoter-driven *Renilla* luciferase in which all DRAC motifs were ablated (m⁶A null *R-Luc*) (Gokhale et al., 2019) and then fused to the wild-type (WT) *IFITM1* 3' UTR or an analogous 3' UTR sequence in which the four putative m⁶A motifs under the m⁶A peak in the 3' UTR in *IFITM1* were inactivated by A \rightarrow G transitions (m⁶A-mut) (Figure 3C). These constructs also express a CMV-promoter-driven m⁶A null firefly luciferase gene as a control. The m⁶A modification status of the *IFITM1* 3' UTR reporter was first assessed using MeRIP-qRT-PCR after IFN- β treatment. The WT *IFITM1* 3' UTR reporter had increased m⁶A compared to the m⁶A-mut *IFITM1* 3' UTR reporter, as well as the negative control *HPRT1*, which does not contain m⁶A (Wang et al., 2014), and an m⁶A-negative synthetic RNA control (Figure 3D). Additionally, METTL3/14 depletion decreased m⁶A modification on the WT *IFITM1* 3' UTR reporter but not the m⁶A-mut *IFITM1* 3' UTR reporter or the m⁶A-negative synthetic RNA control (Figure 3E), suggesting that METTL3/14 is responsible for m⁶A addition to the WT *IFITM1* 3' UTR reporter. We next compared the expression of the WT and m⁶A-mut *IFITM1* reporters at the mRNA and protein level. The *Renilla* mRNA levels following IFN- β treatment were similar for both the WT and m⁶A-mut *IFITM1* 3' UTR reporters (Figure 3F). However, when we measured *Renilla* luciferase protein expression

from the WT and m⁶A-mut *IFITM1* 3' UTR reporters, relative to firefly luciferase, we found that the relative luciferase activity of the m⁶A-mut *IFITM1* 3' UTR reporter was significantly decreased following IFN- β compared to that of the WT *IFITM1* 3' UTR reporter (Figure 3G). Together, these data suggest that METTL3/14 regulates *IFITM1* translation through addition of m⁶A to the 3' UTR and that m⁶A within the *IFITM1* 3' UTR is sufficient to enhance its translation.

YTHDF1 enhances *IFITM1* protein expression in an m⁶A-dependent fashion

The m⁶A binding protein YTHDF1 enhances translation of a number of m⁶A-modified genes (Wang et al., 2015). To test if YTHDF1 elicited the translation-promoting effects of m⁶A on ISGs, we stably overexpressed YTHDF1 (H7^{Y1}) or an m⁶A-binding-deficient YTHDF1 protein (Xu et al., 2015) (H7^{Y1mut}) in Huh7 cells and measured the IFN-induced expression of ISGs 24 h later, relative to parental Huh7 cells (H7). Overexpression of YTHDF1 was sufficient to increase *IFITM1* protein expression in response to IFN- β , whereas overexpression of the m⁶A-binding-deficient YTHDF1 protein (H7^{Y1mut}) did not increase *IFITM1* abundance (Figures 4A and 4B). Importantly, WT and mutant YTHDF1 overexpression did not significantly affect the levels of *IFITM1* mRNA following IFN- β , suggesting that YTHDF1 does not directly regulate IFN signaling or *IFITM1* mRNA stability (Figure 4C). Neither the IFN-induced expression of the m⁶A-containing ISG MX1, nor the non-m⁶A containing ISGs ISG15 and EIF2AK2, were significantly altered by YTHDF1 overexpression (Figures 4A and 4B). Conversely, depletion of YTHDF1 led to decreased *IFITM1* protein expression following IFN- β treatment, whereas MX1, ISG15, and EIF2AK2 were unaffected (Figure 4D). Interestingly, we found that WT YTHDF1 bound to the transcripts of *IFITM1*, MX1, ISG15, and the m⁶A-positive control SON (Wang et al., 2014), whereas the m⁶A-binding-defective YTHDF1 mutant protein did not. The non-m⁶A containing mRNAs *EIF2AK2* and *RPL30* (Wang et al., 2015) did not bind to either protein (Figures 4E and 4F). Together, these results reveal that YTHDF1 binds to m⁶A on *IFITM1* mRNA and is both necessary and sufficient to enhance its translation through its m⁶A-binding activity. The apparent m⁶A-dependent binding of YTHDF1 to ISG15 mRNA suggests that ISG15 mRNA is actually m⁶A-modified. In fact, plotting MeRIP-seq reads over input reads for ISG15 mRNA did show a potential region of m⁶A enrichment in its 3' UTR (Figure 2E), although this was not identified as significant by two peak callers (Data S2). Thus, YTHDF1 has transcript-specific roles in promoting translation, as it bound the transcripts of *IFITM1*, MX1, and ISG15, but its overexpression was sufficient only to significantly increase the protein production of *IFITM1*.

METTL3/14 and m⁶A promote the translation of a subset of ISGs

To identify additional ISGs whose protein expression is regulated by METTL3/14, we used quantitative mass-spectrometry-based proteomics with stable isotope labeling of amino acids (SILAC) to compare the proteomes of siCTRL and siMETTL3/14 cells after IFN- β treatment (Data S3). The effect of siMETTL3/14 compared to siCTRL on protein abundance is centered at a log ratio of 0 for the majority of proteins (Figure S4A), demonstrating that




Figure 3. m⁶A modification of the IFITM1 3' UTR enhances translation

(A) Representative MeRIP-qRT-PCR analysis of relative m⁶A level of ISGs induced by IFN-β (8 h) in Huh7 cells treated with siCTRL or METTL3/14 siRNA and spiked-in m⁶A-negative (NEG) oligonucleotides.

(B) Relative percent enrichment of each gene in (A), normalized to siCTRL, from 5 biological replicates.

(C) Schematic of WT and mutant ISRE-m⁶A null *Renilla* luciferase (R-Luc) IFITM1 3' UTR reporters that also express m⁶A null firefly luciferase (F-Luc) from a separate promoter.

(D) MeRIP-qRT-PCR analysis of relative m⁶A level of WT and m⁶A-mut IFITM1 3' UTR reporter RNA from transfected Huh7 cells treated with IFN-β (8 h).

(E) MeRIP-qRT-PCR analysis of relative m⁶A level of WT and m⁶A-mut IFITM1 3' UTR reporter RNA from Huh7 transfected with siRNA (24 h), followed by reporter transfection (24 h) and treated with IFN-β (8 h).

(F) qRT-PCR analysis of WT and m⁶A-mut IFITM1 3' UTR reporter mRNA expression normalized to HPRT1 in Huh7 cells following reporter transfection (24 h) and IFN-β treatment (8 h).

(G) Relative luciferase activity (R-Luc/F-Luc) in IFN-β induced (8 h, relative to mock) WT and m⁶A-mut IFITM1 3' UTR reporters.

Values are the mean ± SD of 3 technical replicates representative of 5 biological replicates (A), the mean ± SEM of 5 biological replicates (B), the mean ± SEM of 2 biological replicates (D and F), the mean ± SEM of 3 biological replicates (E), or mean ± SEM of 4 biological replicates (G). *p < 0.05, **p < 0.01 by unpaired Student's t test.

METTL3/14 depletion does not have a global effect on protein levels after IFN-β treatment. We determined which proteins are ISGs by defining ISGs as genes upregulated >2-fold by IFN-β treatment in our previous RNA-seq experiment (Data S1). Although mass spectrometry detection of ISGs was limited (n = 18), we did identify a number of METTL3/14-regulated ISGs (Figure 5A, MS). The protein expression of most of these ISGs was decreased following METTL3/14 depletion, and these ISGs included the previously identified m⁶A-modified IFITM1 (peptides corresponding to IFITM1/2/3) and MX1, as well as additional antiviral ISGs such as OAS2 and the different HLA-C chains (Figure 5A), which are also m⁶A-modified. By comparing these data to our previous RNA-seq experiment (Data S1), we also determined that the effects of METTL3/14 on the protein level of these ISGs are not determined by regulation of their

mRNA expression, as following METTL3/14 depletion, the ISGs in this experiment that were decreased at the protein level did not also have a decrease in mRNA abundance. This suggests translation regulation, as our earlier polysome profiling indicated for IFITM1 and MX1 (Figures 1C and 1D; Figure 5A, RNA). The fact that not all m⁶A-modified ISGs identified by mass spectrometry were regulated by METTL3/14 depletion (Figure 5A, m⁶A) suggests that METTL3/14 and m⁶A regulate a subset of ISGs and support their protein expression.

As a complementary approach, we used Ribo-seq (also called ribosome profiling) to more broadly define the role of METTL3/14 in translational regulation of ISGs (Data S4). As ribosome profiling relies on digestion of mRNA that is not ribosome bound, we first confirmed that reads in the untranslated regions were depleted (Figure S4B). Then, we analyzed the top 100 most




Figure 4. YTHDF1 enhances IFITM1 protein expression in an m⁶A-dependent fashion

(A) Immunoblot analysis of extracts from Huh7 cells stably overexpressing FLAG-YTHDF1 WT (Huh7^{Y1}) or FLAG-YTHDF1 W465A (Xu et al., 2015) (Huh7^{Y1mut}) following mock or IFN-β (24 h) treatment.

(B) Quantification of ISG expression following IFN-β from 3 independent experiments of (A), normalized to total protein and graphed relative to siCTRL.

(C) qRT-PCR analysis of ISG mRNA expression normalized to HPRT1 in Huh7 cells stably overexpressing FLAG-YTHDF1 WT (Huh7^{Y1}) or W465A (Huh7^{Y1mut}) after IFN-β (24 h) treatment.

(D) Immunoblot analysis of extracts from Huh7 cells transfected with siRNAs to YTHDF1 (siY1) or siCTRL prior to mock or IFN-β (24 h) treatment. Data are representative of 3 independent biological experiments.

(E) qRT-PCR analysis of enrichment of mRNAs following immunoprecipitation (IP) of FLAG-YTHDF1 WT (Y1) or W465A (Y1mut) compared to FLAG-GFP from Huh7 cells following IFN-β (8 h). IP values are normalized to input values and plotted as fold enrichment over GFP.

(F) Immunoblot of FLAG-immunoprecipitated and input fractions used in (E).

Values in (B) and (C) are the mean ± SEM of 3 biological replicates. *p < 0.05, by Kruskal-Wallis with Dunn's multiple-comparisons test. Everything unlabeled was not significant with p > 0.05. Values in (E) are the mean ± SD of 3 technical replicates and are representative of 4 independent experiments.

highly induced ISGs (Data S1) that were actively translated (base mean, >25) and compared the effect of METTL3/14 depletion on ribosome density (Ribo) to mRNA abundance from our previous RNA-seq analysis (RNA) (Figure 5B; Figure S4C; Data S1). METTL3/14 depletion decreased the ribosome occupancy of many of these ISGs (66/100; including *IFITM1*), without having a generalized effect on their mRNA abundance (Figure S4C). In many cases, METTL3/14 depletion affected both the mRNA abundance and ribosome protection of individual ISGs similarly (Figure 5B, quadrants I and III). However, for one-third (33/100) of these ISGs, METTL3/14 depletion decreased ribosome protection, despite greater mRNA abundance (Figure 5B, quadrant IV). Alternatively, very few (4/100) ISGs had both increased ribosome protection and decreased mRNA abundance following METTL3/14 depletion (Figure 5B, quadrant II). Of these 100 ISGs, 85 were m⁶A-modified, which is roughly consistent with the 74% of genes that we had identified in the total expressed transcriptome as containing m⁶A (Data S2). Interestingly, a number of m⁶A-modified ISGs were not regulated by METTL3/14, as measured by ribosome protection or mRNA abundance, sup-

porting a role for METTL3/14 and m⁶A in regulation of only certain ISGs. These data, taken together with our quantitative mass spectrometry and RNA-seq analysis, suggest that METTL3/14 regulates the translation of a subset of ISGs to support their protein expression during the type I IFN response.

METTL3/14 augments the antiviral effects of the IFN response

The fact that METTL3/14 enhances the expression of a subset of ISGs during the type I IFN response suggests that it could be required for an optimal antiviral response. Thus, we measured the ability of type I IFN to restrict infection by the negative-sense stranded RNA virus VSV, following METTL3/14 perturbation. The VSV genome contains the m⁶A_m cap modification, but as the deposition of this modification is not controlled by METTL3/14 (Boulias et al., 2019; Ogino and Banerjee, 2011; Sendinc et al., 2019), we would not expect VSV replication to be directly affected by perturbation of METTL3/14. Rather, any impact on VSV replication would likely be mediated by methylation of host transcripts. We perturbed the expression of METTL3/14




Figure 5. METTL3/14 regulates the translation of a subset of ISGs

(A) A 3-column heatmap shows the effect of METTL3/14 depletion on the expression of ISGs in Huh7 cells following IFN- β treatment. The first column shows the log₂ fold change of protein estimates from quantitative mass spectrometry (siMETTL3/14 over siCTRL + IFN- β 24 h; n = 2 biological replicates). The second column shows log₂ fold change of mRNA reads from an independent RNA-seq experiment (siMETTL3/14 over siCTRL + IFN- β 8 h; n = 3 biological replicates), and the third column indicates m⁶A status (+ indicates m⁶A-positive; — indicates m⁶A-negative) from MeRIP-seq (+ IFN- β 8 h; n = 3 biological replicates). Genes include any ISGs induced more than 2-fold by IFN from RNA-seq that were also detected by mass spectrometry. ISGs investigated in other figures are shown in bold. Because IFITM1/2/3 are similar, we used this notation to indicate peptides detected from this family of proteins; however, RNA-seq fold change and m⁶A status correspond to the underlined number. * adjusted p < 0.05.

(B) Four-quadrant scatterplot showing the effect of METTL3/14 depletion on the expression of ISGs. The y axis is the log₂ fold change of ribosome-protected fragments from Ribo-seq (siMETTL3/14 over siCTRL), and the x axis is the log₂ fold change of mRNA reads from an independent RNA-seq experiment (siMETTL3/14 over siCTRL). m⁶A-modified (blue) or m⁶A-negative (gray) genes are noted. ISGs investigated in other figures are labeled.

See also Figure S4.

by using small interfering RNA (siRNAs) or by overexpression and then determined the percent of cells infected by VSV at 6 h post-infection in the presence and absence of a low dose of IFN- β pretreatment (6 h; 40 U/mL) by using microscopy. Measuring VSV infection at early time points after infection allowed us to measure viral replication prior to cellular upregulation of ISGs induced directly by infection. Indeed, in the absence of IFN- β pretreatment, we saw no induction of ISGs by VSV under any condition (Figures 6A and 6B). Additionally, as anticipated, we found that VSV replication, as measured by immunoblotting or quantifying the percent of cells infected, was not altered by depletion or overexpression of METTL3/14 in the absence of IFN- β (Figure 6). As observed earlier, following IFN- β pretreatment, METTL3/14 depletion led to decreased

expression of METTL3/14-regulated ISGs (Figure 6A), whereas METTL3/14 overexpression increased their expression (Figure 6B). Although IFN- β pretreatment reduced VSV replication, as expected (Müller et al., 1994), depletion of METTL3/14 reduced the ability of IFN- β to restrict VSV, whereas overexpression enhanced IFN-mediated restriction of VSV. (Figure 6). Similar results were seen by flow cytometry, in which METTL3/14 depletion reduced IFN-mediated restriction of VSV at multiple dosages of IFN- β and at differing multiplicities of infection (MOIs) (Figures S5A–S5C). In similar experiments, we measured VSV RNA genome levels by qRT-PCR, as well as the infectious titer produced, and again observed that METTL3/14 depletion reduced IFN-mediated restriction of VSV (Figures S5D and S5E). Together, these data indicate that METTL3/14 enhances




Figure 6. METTL3/14 augments the antiviral effects of the type I IFN response

(A and B) Representative immunoblot analysis ($n = 3$) of extracts from Huh7 cells transfected with siRNAs (A) or stably overexpressing FLAG-METTL14, which also enhances METTL3 expression (M3/14^{OE}); and then treated with IFN- β (6 h) or mock, followed by infection with VSV (MOI = 2; 6 h) (B). Arrows denote FLAG-METTL14 (top) and endogenous METTL14 (bottom).

(C and D) Representative micrographs of Huh7 cells treated with siCTRL or METTL3/14 siRNA (C) or stably overexpressing FLAG-METTL14 (METTL3/14^{OE}; D), that were pre-treated with IFN- β (6 h), and then infected with VSV (MOI = 2; 6 h), with quantification of percent of cells infected from 3 independent experiments with 5 fields per condition, with > 150 cells per field, normalized to siCTRL or WT with no IFN treatment, shown on the right. Scale bar, 100 μ m.

Values are the mean \pm SEM of 3 biological replicates. * $p < 0.05$, *** $p < 0.001$ by 2-way ANOVA with Sidak's multiple comparisons test.

the antiviral properties of type I IFN and is required for an efficient IFN-mediated antiviral response.

DISCUSSION

Post-transcriptional control of the type I IFN response remains poorly understood, and most of our existing knowledge centers around miRNA-mediated regulation of the IFN-induced JAK-STAT signaling pathway (Forster et al., 2015) or a few examples of alternative splicing of ISG transcripts (West et al., 2019). Although studies have documented non-canonical activation or delayed stimulation of subsets of ISGs during viral infection, the molecular pathways that control these subsets of ISGs are not well understood (Pulit-Penaloza et al., 2012; Rose et al., 2010). However, transcriptional regulators of subsets of ISGs have been identified (Froggatt et al., 2019; Perwitasari et al., 2011; Seifert et al., 2019), and the mRNA Cap1 methyltransferase CMTR1

can regulate the expression of certain ISGs (Williams et al., 2020). These studies demonstrate that the complexity of ISG regulation extends beyond transcriptional induction. Here, we identify m⁶A as having a role in post-transcriptional control of a subset of antiviral ISGs. We found that the m⁶A methyltransferase complex of METTL3/14 methylates certain antiviral ISGs to facilitate their translation to promote an antiviral cellular state. Indeed, we found that many ISGs are m⁶A-modified, and our data suggest that translation enhancement may be the primary function for m⁶A on these transcripts. As the type I IFN response must be efficient to limit viral replication, this post-transcriptional enhancement of ISG expression facilitates the efficient establishment of an antiviral cellular state.

The transcript-specific effects of m⁶A can modulate gene expression to coordinate cellular responses. Indeed, we found that the presence of m⁶A on ISGs can elicit different mechanisms of post-transcriptional regulation. For *IFITM1*, m⁶A in the 3' UTR

led to an increase in its translation, by METTL3/14 and the reader protein YTHDF1. Consistent with our results, previous reports have shown that 3' UTR m⁶A modification enhances translation initiation and that YTHDF1 likely mediates this enhancement by recruiting eIF3 to m⁶A-modified mRNAs (Wang et al., 2015). Interestingly, although the m⁶A-modified *MX1* is also upregulated at the protein level by METTL3/14, YTHDF1 overexpression was not sufficient to elicit this upregulation. This finding may indicate that *MX1* requires other factors or additional readers to enhance its expression. Indeed, YTHDF3 has recently been shown to have roles in promoting translation of m⁶A-modified genes, perhaps by its interaction with proteins of the 40S and 60S ribosomal subunits (Li et al., 2017a; Shi et al., 2017), and YTHDC2 can recognize m⁶A within coding sequence to enhance translation (Mao et al., 2019). Of note, others have found that YTHDF3 inhibits ISG production in murine models through its enhancement of *FOXO3* translation, although this apparently occurred independently of m⁶A (Zhang et al., 2019b). Therefore, m⁶A and its related proteins can regulate ISG expression through a variety of mechanisms. Indeed, only a subset of our identified m⁶A-modified ISGs were translationally enhanced by METTL3/14, as shown by a combination of Ribo-seq, quantitative mass spectrometry, and RNA-seq (Figure 5). It is possible that genetic knockout of METTL3/14 would reveal additional ISGs whose translation is regulated by m⁶A, as METTL3/14 may be sufficient to function at low levels, even following siRNA depletion (Schwartz et al., 2014). However, Huh7 cells and other cancer cell lines do not tolerate full METTL3 knockout (Lin et al., 2016). Additionally, as m⁶A has multiple functions in mRNA metabolism, it is possible that m⁶A affects processes other than translation for these other modified ISGs, for example by modulating their splicing, nuclear export, secondary structure, or stability (Liu et al., 2019a). Indeed, it is likely that *ISG15* mRNA stability is regulated by m⁶A, as we found that this transcript is bound by YTHDF1, appears to have an m⁶A site in its 3' UTR, and its mRNA levels are increased following METTL3/14 depletion. m⁶A may also regulate mRNA trafficking or turnover of ISGs at later time points after IFN stimulation or may contribute to alternative splicing of antiviral genes in response to IFN.

Disentangling the regulatory effects of m⁶A on viral infection has been challenging, as both viral and host transcripts contain m⁶A (Williams et al., 2019). Recent work by us and others has shown that m⁶A regulates several aspects of the host response to infection (Gokhale et al., 2019; Rubio et al., 2018; Winkler et al., 2019). For example, when the *IFNB1* transcript is induced, such as in viral infection, it is m⁶A-modified, and this destabilizes the transcript. This regulation of *IFNB1* may serve as an intrinsic mechanism to dampen and control the innate immune response (Rubio et al., 2018; Winkler et al., 2019). Interestingly, HCMV appears to hijack this arm of immune regulation by upregulating METTL3/14 to increase m⁶A on *IFNB1*, which ultimately decreases IFN- β production, resulting in enhanced viral replication (Rubio et al., 2018; Winkler et al., 2019). Our work reveals additional m⁶A-mediated regulation of certain ISGs downstream of IFN- β production. Specifically, we show that METTL3/14 depletion reduces the ability of IFN to restrict VSV, whereas METTL3/14 overexpression has the opposite effect (Figure 6). Importantly,

as VSV replication was not affected by changes in METTL3/14 expression in the absence of IFN, this suggests that the differential ability of IFN to restrict VSV following perturbation of METTL3/14 expression is not mediated by direct regulation of the viral RNA (Figure 6). Rather, these data support the idea that METTL3/14 augments the antiviral response by enhancing the production of ISGs. The regulatory effects of m⁶A at the virus-host interface are complex (McFadden and Horner, 2020), and understanding the effects of m⁶A on host responses to viral infection will be important for the development of m⁶A-centered therapeutic strategies. Furthermore, understanding how m⁶A can regulate immune responses, including IFN- β production and the response to type I IFN, is essential to reveal the influences of m⁶A on viral infection. Indeed, both the ability to efficiently mount antiviral responses and to shut down pro-inflammatory responses are essential for infection outcome, and m⁶A contributes to this balance in multiple ways. Research exploring the cell type specificity of m⁶A regulation of IFN- β and the IFN response will be an interesting future direction. Indeed, m⁶A can regulate the functions of immune cells, such as dendritic cells and T cells (Han et al., 2019; Li et al., 2017b; Wang et al., 2019). Gaining a better understanding of how m⁶A regulates IFN production and responses in immune cells will be of interest. Indeed, most cell types can respond to type I IFNs (de Weerd and Nguyen, 2012), and type I IFNs signal to uninfected bystander cells in paracrine fashion to establish antiviral responses. We found that METTL3/14 regulates certain ISGs in multiple cell types, including primary neonatal human fibroblasts. Identifying the factors that control m⁶A addition to specific ISGs will be an important future pursuit and may clarify why only some of these antiviral genes become methylated. Many type I IFN-stimulated genes are also induced by type II (IFN- γ) and type III (IFN- λ) IFNs. Future studies may uncover whether signaling downstream of these IFNs also leads to m⁶A-mediated modulation of ISG expression. Additionally, exploring whether viruses use strategies to counter METTL3/14-mediated enhancement of ISGs will shed further light on the interplay between viral and host RNA processes and how RNA modifications regulate these processes.

In addition to regulating type I IFN pathways, m⁶A tunes other cellular responses to viral infection. We recently showed changes to the m⁶A status of certain host transcripts in response to *Flaviviridae* infection and that many of these m⁶A-altered genes regulate *Flaviviridae* infection (Gokhale et al., 2019). Some of the alterations in m⁶A during infection were driven by innate immune-sensing pathways, revealing that innate immune activation can affect cellular m⁶A distribution during infection. Others have recently shown that VSV impairs the demethylase activity of ALKBH5, leading to increased m⁶A modification and destabilization of the *OGDH* transcript. This resulted in less production of the metabolite itaconate, which appeared to be required for VSV replication (Liu et al., 2019b). Although these effects of m⁶A on VSV occurred independently of IFN signaling, our work revealed that m⁶A can also inhibit VSV replication by promoting ISG expression during IFN signaling. Although we did not find an effect of m⁶A on VSV in the absence of IFN signaling, as described above (Liu et al., 2019b), we did not investigate a role for ALKBH5. Taken together, our findings add to the

knowledge of the diverse regulatory functions of m⁶A during host-pathogen interactions.

In summary, we reveal specific ISGs that are post-transcriptionally regulated by METTL3/14 through m⁶A modification. Additionally, we show that their translation is enhanced by m⁶A and postulate that m⁶A may be used during the IFN response as a strategy for efficient production of antiviral proteins and the establishment of an antiviral cellular state. Together, these data provide an enhanced molecular understanding of type I IFN response regulation that will ultimately broaden our understanding of innate immunity and host-pathogen interactions. In addition to their antiviral innate immunity functions, ISGs can also regulate inflammation and cell death, as well as even cancer and embryonic development (Buchrieser et al., 2019; Cheon et al., 2014; Yockey and Iwasaki, 2018). Therefore, characterizing the molecular mechanisms that govern ISG expression will be essential for understanding their dysregulation. This information could be harnessed to develop therapeutics to alter ISG expression, with relevance to multiple diseases.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead contact
 - Materials availability
 - Data and Code Availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Cell Culture
- METHOD DETAILS
 - IFN- β Treatment.
 - VSV Infection
 - Microscopy to determine percent of cells infected by VSV
 - Flow Cytometry to determine percent of cells infected by VSV
 - Experimental Titration of VSV-infected supernatants
 - Plasmids
 - Transfection
 - Generation of Overexpression Cell Lines
 - Immunoblotting
 - Quantification of Immunoblots
 - MeRIP-seq
 - RT-qPCR
 - Nuclear/Cytoplasmic Fractionation
 - Protein Stability Analysis
 - Polysome Profiling
 - MeRIP-RT-qPCR
 - Luciferase Assays
 - RNA Immunoprecipitation
 - RNA-seq
 - Ribo-seq
 - Mass Spectrometry
- QUANTIFICATION AND STATISTICAL ANALYSIS
 - MeRIP-seq Data Analysis

- RNA-seq and Ribo-seq Data Analysis
- Mass Spectrometry Data Analysis
- Peptide regression modeling
- Aggregating proteins for gene-level results:

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2021.108798>.

ACKNOWLEDGMENTS

We thank colleagues who provided reagents (see STAR methods), New England Biolabs for the anti-m⁶A antibodies, the Duke Functional Genomics Core, the Duke Center for Genomic and Computational Biology Core, the Weill Cornell Epigenomics Core and Scientific Computing Unit, Jeff Bourgeois and Dr. Dennis Ko for flow cytometry assistance, and Horner lab members for discussion. This work was supported by Burroughs Wellcome Fund (S.M.H.) and National Institutes of Health grants R01AI125416, R21AI129851 (S.M.H. and C.E.M.), R01MH117406 (C.E.M.), T32-CA009111 (M.J.M.), and R01-GM127802 (B.X.). Other funding sources include National Science and Engineering Research Council of Canada (A.B.R.M., PGS-D funding); American Heart Association (N.S.G., Pre-doctoral Fellowship, 17PRE33670017); National Institute of General Medical Sciences of the National Institutes of Health Medical Scientist Training Program grant to the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program (H.M., T32GM007739); Bert L. and N. Kuggie Vallee Foundation; WorldQuant Foundation; Pershing Square Sohn Cancer Research Alliance; and NASA (NNX14AH50G).

AUTHOR CONTRIBUTIONS

Conceptualization: M.J.M. and S.M.H.; investigation: M.J.M., N.S.G., and H.I.; formal analysis: M.J.M., A.B.R.M., H.M., and N.S.A.; software: A.B.R.M., H.M., and N.S.A.; writing – original draft: M.J.M. and S.M.H.; writing – review & editing: M.J.M., A.B.R.M., H.M., N.S.A., N.S.G., B.X., C.E.M., and S.M.H.; funding acquisition: M.J.M., A.B.R.M., N.S.G., B.X., C.E.M., and S.M.H.

DECLARATION OF INTERESTS

C.E.M. is a cofounder and board member for Biotia and Onegevity Health and an advisor or compensated speaker for Abbvie, Acumark Diagnostics, Arc-Bio, Bio-Rad, DNA Genotek, Genialis, Genpro, Illumina, New England Biolabs, QIAGEN, Whole Biome, and Zymo Research.

Received: August 25, 2020
Revised: December 18, 2020
Accepted: February 5, 2021
Published: March 2, 2021

REFERENCES

- Abell, N.S., Mercado, M., Cañeque, T., Rodríguez, R., and Xhemalce, B. (2017). Click Quantitative Mass Spectrometry Identifies PIWIL3 as a Mechanistic Target of RNA Interference Activator Enoxacin in Cancer Cells. *J. Am. Chem. Soc.* 139, 1400–1403.
- Alvarez, M.I., Glover, L.C., Luo, P., Wang, L., Theusch, E., Oehlers, S.H., Walton, E.M., Tram, T.T.B., Kuang, Y.L., Rotter, J.I., et al. (2017). Human genetic variation in *VAC14* regulates *Salmonella* invasion and typhoid fever through modulation of cholesterol. *Proc. Natl. Acad. Sci. USA* 114, E7746–E7755.
- Banchereau, J., and Pascual, V. (2006). Type I interferon in systemic lupus erythematosus and other autoimmune diseases. *Immunity* 25, 383–392.
- Bates, D., Mächler, M., Bolker, B., and Walker, S. (2015). Fitting Linear Mixed-Effects Models Using lme4. *J. Stat. Softw.* 67, 48.
- Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30, 2114–2120.

- Boulias, K., Toczyłowska-Socha, D., Hawley, B.R., Liberman, N., Takashima, K., Zaccara, S., Guez, T., Vasseur, J.J., Debart, F., Aravind, L., et al. (2019). Identification of the m⁶Am Methyltransferase PCIF1 Reveals the Location and Functions of m⁶Am in the Transcriptome. *Mol. Cell* 75, 631–643.e8.
- Buchrieser, J., Degrelle, S.A., Couderc, T., Nevers, Q., Disson, O., Manet, C., Donahue, D.A., Porrot, F., Hillion, K.H., Perthame, E., et al. (2019). IFITM proteins inhibit placental syncytiotrophoblast formation and promote fetal demise. *Science* 365, 176–180.
- Chen, Y.G., Chen, R., Ahmad, S., Verma, R., Kasturi, S.P., Amaya, L., Broughton, J.P., Kim, J., Cadena, C., Pulendran, B., et al. (2019). N6-Methyladenosine Modification Controls Circular RNA Immunity. *Mol. Cell* 76, 96–109.e9.
- Cheon, H., Borden, E.C., and Stark, G.R. (2014). Interferons and their stimulated genes in the tumor microenvironment. *Semin. Oncol.* 41, 156–173.
- Coots, R.A., Liu, X.M., Mao, Y., Dong, L., Zhou, J., Wan, J., Zhang, X., and Qian, S.B. (2017). m(6)A Facilitates eIF4F-Independent mRNA Translation. *Mol. Cell* 68, 504–514.e7.
- Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* 26, 1367–1372.
- Cox, J., Neuhauser, N., Michalski, A., Scheltema, R.A., Olsen, J.V., and Mann, M. (2011). Andromeda: a peptide search engine integrated into the MaxQuant environment. *J. Proteome Res.* 10, 1794–1805.
- Cui, X., Zhang, L., Meng, J., Rao, M.K., Chen, Y., and Huang, Y. (2018). MeT-Diff: A Novel Differential RNA Methylation Analysis for MeRIP-Seq Data. *IEEE/ACM Trans. Comput. Biol. Bioinformatics* 15, 526–534.
- de Weerd, N.A., and Nguyen, T. (2012). The interferons and their receptors—distribution and regulation. *Immunol. Cell Biol.* 90, 483–491.
- Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 29, 15–21.
- Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., Osenberg, S., Cesarkas, K., Jacob-Hirsch, J., Amariglio, N., Kupiec, M., et al. (2012). Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. *Nature* 485, 201–206.
- Durbin, A.F., Wang, C., Marcotrigiano, J., and Gehrke, L. (2016). RNAs Containing Modified Nucleotides Fail To Trigger RIG-I Conformational Changes for Innate Immune Signaling. *mBio* 7, e00833-16.
- Fang, T.C., Schaefer, U., Mecklenbrauker, I., Stienen, A., Dewell, S., Chen, M.S., Rioja, I., Parravicini, V., Prinjha, R.K., Chandwani, R., et al. (2012). Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. *J. Exp. Med.* 209, 661–669.
- Feng, Z., Li, Q., Meng, R., Yi, B., and Xu, Q. (2018). METTL3 regulates alternative splicing of MyD88 upon the lipopolysaccharide-induced inflammatory response in human dental pulp cells. *J. Cell. Mol. Med.* 22, 2558–2568.
- Forster, S.C., Tate, M.D., and Hertzog, P.J. (2015). MicroRNA as Type I Interferon-Regulated Transcripts and Modulators of the Innate Immune Response. *Front. Immunol.* 6, 334.
- Froggatt, H.M., Harding, A.T., and Heaton, N.S. (2019). ETV7 represses a subset of interferon-stimulated genes that restrict influenza viruses. *bioRxiv*. <https://doi.org/10.1101/851543>.
- Gokhale, N.S., McIntyre, A.B.R., Mattocks, M.D., Holley, C.L., Lazear, H.M., Mason, C.E., and Horner, S.M. (2019). Altered m(6)A Modification of Specific Cellular Transcripts Affects Flaviviridae Infection. *Mol. Cell* 77, 542–555.e8.
- Gokhale, N.S., McIntyre, A.B., McFadden, M.J., Roder, A.E., Kennedy, E.M., Gandara, J.A., Hopcraft, S.E., Quicke, K.M., Vazquez, C., Willer, J., et al. (2016). N6-Methyladenosine in Flaviviridae Viral RNA Genomes Regulates Infection. *Cell Host Microbe* 20, 654–665.
- González-Navajas, J.M., Lee, J., David, M., and Raz, E. (2012). Immunomodulatory functions of type I interferons. *Nat. Rev. Immunol.* 12, 125–135.
- Han, D., Liu, J., Chen, C., Dong, L., Liu, Y., Chang, R., Huang, X., Liu, Y., Wang, J., Dougherty, U., et al. (2019). Anti-tumour immunity controlled through mRNA m⁶A methylation and YTHDF1 in dendritic cells. *Nature* 566, 270–274.
- Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., and Glass, C.K. (2010). Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* 38, 576–589.
- Huang, M., Qian, F., Hu, Y., Ang, C., Li, Z., and Wen, Z. (2002). Chromatin-re-modelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes. *Nat. Cell Biol.* 4, 774–781.
- Imam, H., Khan, M., Gokhale, N.S., McIntyre, A.B.R., Kim, G.W., Jang, J.Y., Kim, S.J., Mason, C.E., Horner, S.M., and Siddiqui, A. (2018). N6-methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle. *Proc. Natl. Acad. Sci. USA* 115, 8829–8834.
- Karikó, K., Buckstein, M., Ni, H., and Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity* 23, 165–175.
- Kennedy, E.M., Bogerd, H.P., Kornepati, A.V., Kang, D., Ghoshal, D., Marshall, J.B., Poling, B.C., Tsai, K., Gokhale, N.S., Horner, S.M., and Cullen, B.R. (2016). Posttranscriptional m(6)A Editing of HIV-1 mRNAs Enhances Viral Gene Expression. *Cell Host Microbe* 19, 675–685.
- Lesbirel, S., and Wilson, S.A. (2019). The m⁶A-methylase complex and mRNA export. *Biochim. Biophys. Acta. Gene Regul. Mech.* 1862, 319–328.
- Li, A., Chen, Y.S., Ping, X.L., Yang, X., Xiao, W., Yang, Y., Sun, H.Y., Zhu, Q., Baidya, P., Wang, X., et al. (2017a). Cytoplasmic m⁶A reader YTHDF3 promotes mRNA translation. *Cell Res.* 27, 444–447.
- Li, H.B., Tong, J., Zhu, S., Batista, P.J., Duffy, E.E., Zhao, J., Bailis, W., Cao, G., Kroehling, L., Chen, Y., et al. (2017b). m⁶A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. *Nature* 548, 338–342.
- Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 30, 923–930.
- Lin, S., Choe, J., Du, P., Triboulet, R., and Gregory, R.I. (2016). The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. *Mol. Cell* 62, 335–345.
- Liu, H., Kang, H., Liu, R., Chen, X., and Zhao, K. (2002). Maximal induction of a subset of interferon target genes requires the chromatin-remodeling activity of the BAF complex. *Mol. Cell. Biol.* 22, 6471–6479.
- Liu, J., Yue, Y., Han, D., Wang, X., Fu, Y., Zhang, L., Jia, G., Yu, M., Lu, Z., Deng, X., et al. (2014). A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. *Nat. Chem. Biol.* 10, 93–95.
- Liu, J., Harada, B.T., and He, C. (2019a). Regulation of Gene Expression by N⁶-methyladenosine in Cancer. *Trends Cell Biol.* 29, 487–499.
- Liu, Y., You, Y., Lu, Z., Yang, J., Li, P., Liu, L., Xu, H., Niu, Y., and Cao, X. (2019b). N⁶-methyladenosine RNA modification-mediated cellular metabolism rewiring inhibits viral replication. *Science* 365, 1171–1176.
- Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550.
- Lu, M., Zhang, Z., Xue, M., Zhao, B.S., Harder, O., Li, A., Liang, X., Gao, T.Z., Xu, Y., Zhou, J., et al. (2020). N⁶-methyladenosine modification enables viral RNA to escape recognition by RNA sensor RIG-I. *Nat. Microbiol.* 5, 584–598.
- Mao, Y., Dong, L., Liu, X.M., Guo, J., Ma, H., Shen, B., and Qian, S.B. (2019). m⁶A in mRNA coding regions promotes translation via the RNA helicase-containing YTHDC2. *Nat. Commun.* 10, 5332.
- Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet. J.* 17, 10–12.
- McFadden, M.J., and Horner, S.M. (2020). N(6)-Methyladenosine Regulates Host Responses to Viral Infection. *Trends Biochem. Sci.* Published online December 9, 2020. <https://doi.org/10.1016/j.tibs.2020.11.008>.
- McIntyre, A.B.R., Gokhale, N.S., Cerchielli, L., Jaffrey, S.R., Horner, S.M., and Mason, C.E. (2020). Limits in the detection of m⁶A changes using MeRIP/m⁶A-seq. *Sci. Rep.* 10, 6590.

- Metsalu, T., and Vilo, J. (2015). ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. *Nucleic Acids Res.* **43**, W566–W570.
- Meyer, K.D., and Jaffrey, S.R. (2017). Rethinking m⁶A Readers, Writers, and Erasers. *Annu. Rev. Cell Dev. Biol.* **33**, 319–342.
- Meyer, K.D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C.E., and Jaffrey, S.R. (2012). Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. *Cell* **149**, 1635–1646.
- Miller, D.M., Zhang, Y., Rahill, B.M., Waldman, W.J., and Sedmak, D.D. (1999). Human cytomegalovirus inhibits IFN- α -stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN- α signal transduction. *J. Immunol.* **162**, 6107–6113.
- Müller, U., Steinhoff, U., Reis, L.F., Hemmi, S., Pavlovic, J., Zinkernagel, R.M., and Aguet, M. (1994). Functional role of type I and type II interferons in antiviral defense. *Science* **264**, 1918–1921.
- Ogino, T., and Banerjee, A.K. (2011). An unconventional pathway of mRNA cap formation by vesiculoviruses. *Virus Res.* **162**, 100–109.
- Pervitasari, O., Cho, H., Diamond, M.S., and Gale, M., Jr. (2011). Inhibitor of κ B kinase epsilon (IKK(epsilon)), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection. *J. Biol. Chem.* **286**, 44412–44423.
- Ping, X.L., Sun, B.F., Wang, L., Xiao, W., Yang, X., Wang, W.J., Adhikari, S., Shi, Y., Lv, Y., Chen, Y.S., et al. (2014). Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. *Cell Res.* **24**, 177–189.
- Pulit-Penaloza, J.A., Scherbik, S.V., and Brinton, M.A. (2012). Type I IFN-independent activation of a subset of interferon stimulated genes in West Nile virus Egt101-infected mouse cells. *Virology* **425**, 82–94.
- Ramírez, F., Ryan, D.P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A.S., Heyne, S., Dündar, F., and Manke, T. (2016). deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res.* **44**, W160–W165.
- Rose, K.M., Elliott, R., Martínez-Sobrido, L., García-Sastre, A., and Weiss, S.R. (2010). Murine coronavirus delays expression of a subset of interferon-stimulated genes. *J. Virol.* **84**, 5656–5669.
- Rubio, R.M., Depledge, D.P., Bianco, C., Thompson, L., and Mohr, I. (2018). RNA m⁶A modification enzymes shape innate responses to DNA by regulating interferon β . *Genes Dev.* **32**, 1472–1484.
- Schoggins, J.W. (2014). Interferon-stimulated genes: roles in viral pathogenesis. *Curr. Opin. Virol.* **6**, 40–46.
- Schoggins, J.W. (2019). Interferon-Stimulated Genes: What Do They All Do? *Annu. Rev. Virol.* **6**, 567–584.
- Schoggins, J.W., and Rice, C.M. (2011). Interferon-stimulated genes and their antiviral effector functions. *Curr. Opin. Virol.* **1**, 519–525.
- Schwartz, S., Mumbach, M.R., Jovanovic, M., Wang, T., Maciag, K., Bushkin, G.G., Mertins, P., Ter-Ovanesyan, D., Habib, N., Cacchiarelli, D., et al. (2014). Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. *Cell Rep.* **8**, 284–296.
- Seifert, L.L., Si, C., Saha, D., Sadic, M., de Vries, M., Ballentine, S., Briley, A., Wang, G., Valero-Jimenez, A.M., Mohamed, A., et al. (2019). The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response. *PLoS Pathog.* **15**, e1007634.
- Sendinc, E., Valle-Garcia, D., Dhall, A., Chen, H., Henriques, T., Navarrete-Perea, J., Sheng, W., Gygi, S.P., Adelman, K., and Shi, Y. (2019). PCIF1 Catalyzes m6Am mRNA Methylation to Regulate Gene Expression. *Mol. Cell* **75**, 620–630.e9.
- Shaw, A.E., Hughes, J., Gu, Q., Behdenna, A., Singer, J.B., Dennis, T., Orton, R.J., Varela, M., Gifford, R.J., Wilson, S.J., and Palmarini, M. (2017). Fundamental properties of the mammalian innate immune system revealed by multi-species comparison of type I interferon responses. *PLoS Biol.* **15**, e2004086.
- Shi, H., Wang, X., Lu, Z., Zhao, B.S., Ma, H., Hsu, P.J., Liu, C., and He, C. (2017). YTHDF3 facilitates translation and decay of N⁶-methyladenosine-modified RNA. *Cell Res.* **27**, 315–328.
- Shi, G., Ozog, S., Torbett, B.E., and Compton, A.A. (2018). mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3. *Proc. Natl. Acad. Sci. USA* **115**, E10069–E10078.
- Shi, H., Wei, J., and He, C. (2019). Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. *Mol. Cell* **74**, 640–650.
- Stark, G.R., and Darnell, J.E., Jr. (2012). The JAK-STAT pathway at twenty. *Immunity* **36**, 503–514.
- Sumpter, R., Jr., Loo, Y.M., Foy, E., Li, K., Yoneyama, M., Fujita, T., Lemon, S.M., and Gale, M., Jr. (2005). Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. *J. Virol.* **79**, 2689–2699.
- Teijaro, J.R. (2016). Type I interferons in viral control and immune regulation. *Curr. Opin. Virol.* **16**, 31–40.
- Wang, X., Lu, Z., Gomez, A., Hon, G.C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., et al. (2014). N6-methyladenosine-dependent regulation of messenger RNA stability. *Nature* **505**, 117–120.
- Wang, X., Zhao, B.S., Roundtree, I.A., Lu, Z., Han, D., Ma, H., Weng, X., Chen, K., Shi, H., and He, C. (2015). N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency. *Cell* **161**, 1388–1399.
- Wang, H., Hu, X., Huang, M., Liu, J., Gu, Y., Ma, L., Zhou, Q., and Cao, X. (2019). Mettl3-mediated mRNA m⁶A methylation promotes dendritic cell activation. *Nat. Commun.* **10**, 1898.
- West, K.O., Scott, H.M., Torres-Odio, S., West, A.P., Patrick, K.L., and Watson, R.O. (2019). The Splicing Factor hnRNP M Is a Critical Regulator of Innate Immune Gene Expression in Macrophages. *Cell Rep.* **29**, 1594–1609.e1595.
- Whelan, S.P., Barr, J.N., and Wertz, G.W. (2000). Identification of a minimal size requirement for termination of vesicular stomatitis virus mRNA: implications for the mechanism of transcription. *J. Virol.* **74**, 8268–8276.
- Williams, G.D., Gokhale, N.S., and Horner, S.M. (2019). Regulation of Viral Infection by the RNA Modification N6-Methyladenosine. *Annu. Rev. Virol.* **6**, 235–253.
- Williams, G.D., Gokhale, N.S., Snider, D.L., and Horner, S.M. (2020). The mRNA Cap 2'-O-Methyltransferase CMTR1 Regulates the Expression of Certain Interferon-Stimulated Genes. *MSphere* **5**, e00202-20.
- Winkler, R., Gillis, E., Lasman, L., Safran, M., Geula, S., Soyris, C., Nachshon, A., Tai-Schmiedel, J., Friedman, N., Le-Trilling, V.T.K., et al. (2019). m⁶A modification controls the innate immune response to infection by targeting type I interferons. *Nat. Immunol.* **20**, 173–182.
- Xie, M., Xuan, B., Shan, J., Pan, D., Sun, Y., Shan, Z., Zhang, J., Yu, D., Li, B., and Qian, Z. (2015). Human cytomegalovirus exploits interferon-induced transmembrane proteins to facilitate morphogenesis of the virion assembly compartment. *J. Virol.* **89**, 3049–3061.
- Xu, C., Liu, K., Ahmed, H., Loppnau, P., Schapira, M., and Min, J. (2015). Structural Basis for the Discriminative Recognition of N6-Methyladenosine RNA by the Human YT521-B Homology Domain Family of Proteins. *J. Biol. Chem.* **290**, 24902–24913.
- Yockey, L.J., and Iwasaki, A. (2018). Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development. *Immunity* **49**, 397–412.
- Zaccara, S., and Jaffrey, S.R. (2020). A Unified Model for the Function of YTHDF Proteins in Regulating m(6)A-Modified mRNA. *Cell* **181**, 1582–1595.e1518.
- Zhang, C., Fu, J., and Zhou, Y. (2019a). A Review in Research Progress Concerning m6A Methylation and Immunoregulation. *Front. Immunol.* **10**, 922.
- Zhang, Y., Wang, X., Zhang, X., Wang, J., Ma, Y., Zhang, L., and Cao, X. (2019b). RNA-binding protein YTHDF3 suppresses interferon-dependent antiviral responses by promoting FOXO3 translation. *Proc. Natl. Acad. Sci. USA* **116**, 976–981.
- Zheng, Q., Hou, J., Zhou, Y., Li, Z., and Cao, X. (2017). The RNA helicase DDX46 inhibits innate immunity by entrapping m⁶A-demethylated antiviral transcripts in the nucleus. *Nat. Immunol.* **18**, 1094–1103.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-m ⁶ A	Synaptic Systems	Cat# 202 003; RRID:AB_2279214
Anti-METTL3	Abnova	Cat# H00056339-B01P; RRID:AB_2687437
Anti-METTL14	Sigma-Aldrich	Cat# HPA038002; RRID:AB_10672401
Anti-YTHDF1	Proteintech	Cat# 17479-1-AP; RRID:AB_2217473
Anti-IFITM1	Proteintech	Cat# 60074-1-Ig; RRID:AB_2233405
Anti-MX1	Abcam	Cat# ab207414
Anti-ISG15	Santa Cruz	Cat# sc-166755; RRID:AB_2126308
Anti-EIF2AK2	Abcam	Cat# ab226819
Anti-FLAG-HRP conjugated	Sigma-Aldrich	Cat# A8592; RRID:AB_439702
Anti-GFP	Thermo Fisher Sci.	Cat# A-11122; RRID:AB_221569
Anti-mouse HRP Secondary	Jackson ImmunoResearch	Cat# 115-035-003; RRID:AB_10015289
Anti-rabbit HRP Secondary	Jackson ImmunoResearch	Cat# 111-035-003; RRID:AB_2313567
Bacterial and virus strains		
VSV-GFP	Whelan et al., 2000	N/A
Chemicals, peptides, and recombinant proteins		
Human IFN Beta (Beta 1a, Mammalian)	PBL Assay Science	Cat# 11415-1
N ⁶ -methyladenosine 5' monophosphate salt	Santa Cruz Biotech.	Cat# sc-215524; CAS: 81921-35-9
TRIzol	Thermo Fisher Sci.	Cat# 15596026
Phenol:Chloroform:Isoamyl Alcohol	Thermo Fisher Sci.	Cat# AM9730
NP-40	Thermo Fisher Sci.	Cat# 85124
Puromycin	Sigma-Aldrich	Cat# P8833
Recombinant RNaseIN RNase inhibitor	Promega	Cat# N2511
Protease inhibitor	Sigma-Aldrich	Cat# P8340
Phosphatase inhibitor	Thermo Fisher Sci.	Cat# 78426
Revert 700 Total Protein Stain	LI-COR Biosciences	Cat# 926-11011
BSA (albumin from bovine serum)	Sigma-Aldrich	Cat# A7906
<i>NotI</i> -HF	New England Biolabs	Cat# R3189
<i>XbaI</i>	New England Biolabs	Cat# R0145
<i>KpnI</i> -HF	New England Biolabs	Cat# R3142
<i>NheI</i> -HF	New England Biolabs	Cat# R3131
<i>BamHI</i> -HF	New England Biolabs	Cat# R3136
<i>XhoI</i>	New England Biolabs	Cat# R0146
DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride)	Thermo Fisher Sci.	Cat# D1306
2X Laemmli sample buffer	Bio-Rad	Cat# 161-0737
Protein G Dynabeads	Thermo Fisher Sci.	Cat# 10004D
FLAG M2 conjugated beads	Sigma-Aldrich	Cat# M8823; RRID:AB_2637089
Opti-MEM I reduced serum medium	Thermo Fisher Sci.	Cat# 31985070
DMEM	Mediatech	Cat# 10-013-CV
HEPES (1M)	Thermo Fisher Sci.	Cat# 15630130
MEM Non Essential Amino Acids Solution (100X)	Thermo Fisher Sci.	Cat# 11-140-050
DMEM Media for SILAC	Thermo Fisher Sci.	Cat# A33822
Light L-Arginine-HCl for SILAC	Thermo Fisher Sci.	Cat# PI88427
Heavy L-Arginine-HCl, 13C6, 15N4 for SILAC	Thermo Fisher Sci.	Cat# PI88434

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Light L-Lysine-2HCl for SILAC	Thermo Fisher Sci.	Cat# PI88429
Heavy L-Lysine-2HCl, 13C6, 15N2 for SILAC	Thermo Fisher Sci.	Cat# PI88432

Critical commercial assays

N6-methyladenosine enrichment kit	New England Biolabs	Cat# E1610S
Dynabeads mRNA purification kit	Thermo Fisher Sci.	Cat# 61006
Power SYBR Green PCR master mix	Thermo Fisher Sci.	Cat# 4367659
Dual luciferase reporter assay system	Promega	Cat# E1960
T4 DNA Ligase	New England Biolabs	Cat# M0202S
iScript cDNA synthesis kit	Bio-Rad	Cat# 1708891BUN
Superscript III enzyme	Thermo Fisher Sci.	Cat# 18080044
InFusion HD cloning kit	Takara Bio	Cat# 639650
Quik-change Lightning SDM kit	Agilent	Cat# 210518
RNA fragmentation reagent	Thermo Fisher Sci.	Cat# AM8740
FuGENE 6 transfection reagent	Promega	Cat# E2691
Lipofectamine RNAiMAX transfection reagent	Thermo Fisher Sci.	Cat# 13778150
Phusion High-Fidelity DNA Polymerase	New England Biolabs	Cat# M0530S
TURBO DNase	Thermo Fisher Sci.	Cat# AM2239
Micrococcal Nuclease	New England Biolabs	Cat# M0247

Deposited data

RNA-seq, MeRIP-seq, and Ribo-seq of METTL3/14 depleted Huh7 cells, treated with IFN- β or Mock	This study	GEO: GSE155448
Quantitative mass spectrometry of lysates from METTL3/14-depleted Huh7 cells, treated with IFN- β for 24 hours	This study	https://web.corral.tacc.utexas.edu/xhemalce/Forward1.raw
Quantitative mass spectrometry of lysates from METTL3/14-depleted Huh7 cells, treated with IFN- β for 24 hours	This study	https://web.corral.tacc.utexas.edu/xhemalce/Forward2.raw
Quantitative mass spectrometry of lysates from METTL3/14-depleted Huh7 cells, treated with IFN- β for 24 hours	This study	https://web.corral.tacc.utexas.edu/xhemalce/Reverse1.raw
Quantitative mass spectrometry of lysates from METTL3/14-depleted Huh7 cells, treated with IFN- β for 24 hours	This study	https://web.corral.tacc.utexas.edu/xhemalce/Reverse2.raw

Experimental models: cell lines

Huh7	Gift of Dr. Michael Gale, Jr. (Sumpter et al., 2005)	RRID:CVCL_0336
A549	ATCC	Cat# CCL-185; RRID:CVCL_0023
293T	ATCC	Cat# CRL-3216; RRID:CVCL_0063
Vero	ATCC	Cat# CCL-81; RRID:CVCL_0059
Neonatal Human Dermal Fibroblasts	Lonza	Cat# CC-2509; RRID:CVCL_Z230
Huh7-M3/14 OE (Huh7-FLAG-METTL14)	This study	N/A
Huh7 FLAG-YTHDF1	Gokhale et al., 2016	N/A
Huh7 FLAG-YTHDF1 W465A	This study	N/A

Oligonucleotides

Oligonucleotides for RT-qPCR	Table S5	N/A
Oligonucleotides and gBlocks for Cloning	Table S5	N/A
Oligonucleotides for siRNA	Table S5	N/A

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Recombinant DNA		
pLEX-FLAG-YTHDF1	Kennedy et al., 2016	N/A
psiCheck2-m6A-null	Gokhale et al., 2019	N/A
pLEX-FLAG-METTLL14	This study	N/A
pLEX-FLAG-YTHDF1 W465A	This study	N/A
psiCheck2-m6A-null-ISRE-IFITM1 3' UTR reporter (wild-type)	This study	N/A
psiCheck2-m6A-null-ISRE-IFITM1 3' UTR reporter (m ⁶ A-mut)	This study	N/A
psPAX2	Duke Functional Genomics Core Facility	Addgene plasmid # 12260; RRID: Addgene_12260
pMD2.G	Duke Functional Genomics Core Facility	Addgene Plasmid #12259; RRID: Addgene_12259
Software and algorithms		
ImageStudio	LI-COR Biosciences	RRID:SCR_013715; https://www.licor.com/bio/products/software/image_studio_lite
Prism 8.0	Graphpad	RRID:SCR_002798; https://www.graphpad.com
STAR	Dobin et al., 2013	v2.5.0a; https://github.com/alexdobin/STAR
Cutadapt	Martin, 2011	V2.10; https://cutadapt.readthedocs.io/en/stable/ ; RRID:SCR_011841
MeTDiff	Cui et al., 2018	v1.1.0; https://github.com/compugenomics/MeTDiff
meRIPper	N/A	V0.9.1a; https://sourceforge.net/projects/meripper/
Trimmomatic	Bolger et al., 2014	V0.39; http://www.usadellab.org/cms/index.php?page=trimmomatic ; RRID:SCR_011848
DESeq2	Love et al., 2014	v1.20.0; https://bioconductor.org/packages/release/bioc/html/DESeq2.html
featureCounts	Liao et al., 2014	V2.0.0; http://bioinf.wehi.edu.au/featureCounts/ ; RRID:SCR_012919
CovFuzze	Imam et al., 2018	v0.1.3; https://github.com/al-mcintyre/CovFuzze
HOMER	Heinz et al., 2010	v4.11; http://homer.ucsd.edu/homer/motif/ ; RRID:SCR_010881
deepTools	Ramírez et al., 2016	v3.1; https://deeptools.readthedocs.io/en/develop/ ; RRID:SCR_016366
ClustVis	Metsalu and Vilo, 2015	v0.13; https://biit.cs.ut.ee/clustvis/ ; RRID:SCR_017133
MaxQuant	Cox and Mann, 2008 Cox et al., 2011	v1.6.7.0; https://www.maxquant.org/ ; RRID:SCR_014485
R package: lme4	Bates et al., 2015	v1.1-23; https://cran.r-project.org/web/packages/lme4/index.html

RESOURCE AVAILABILITY

Lead contact

Requests for further information should be directed to and will be fulfilled by the Lead Contact, Stacy M. Horner (stacy.horner@duke.edu).

Materials availability

Requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stacy M. Horner (stacy.horner@duke.edu).

Data and Code Availability

All raw data from RNA-seq, MeRIP-seq, and Ribo-seq are available through GEO (accession number: GSE155448).

Raw data from mass spectrometry are available at the following URLs:

<https://web.corral.tacc.utexas.edu/xhemalce/Forward1.raw>

<https://web.corral.tacc.utexas.edu/xhemalce/Forward2.raw>

<https://web.corral.tacc.utexas.edu/xhemalce/Reverse1.raw>

<https://web.corral.tacc.utexas.edu/xhemalce/Reverse2.raw>

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell Culture

Human hepatoma Huh7 and Huh7.5 cells, lung carcinoma A549 cells, neonatal human dermal fibroblast (NHDF) cells, Vero cells, and embryonic kidney 293T cells were grown in Dulbecco's modification of Eagle's medium (DMEM; Mediatech) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific), 1X minimum essential medium non-essential amino acids (Thermo Fisher Scientific), and 25 mM HEPES (Thermo Fisher Scientific) (cDMEM). The identity of the Huh7 cells used in this study was verified by using the GenePrint STR kit (Promega) (DNA Analysis Facility, Duke University, Durham, NC, USA). A549 cells, 293T, and Vero cells (CCL-185, CRL-3216, and CCL-81) were obtained from American Type Culture Collection (ATCC), NHDF cells (CC-2509) were obtained from Lonza, and Huh7 cells were a gift of Dr. Michael Gale. All cell lines were verified as mycoplasma free by the LookOut Mycoplasma PCR detection kit (Sigma).

METHOD DETAILS

IFN- β Treatment.

All IFN- β (PBL Assay Science) treatments were performed at a concentration of 50 units/mL in cDMEM, unless otherwise noted.

VSV Infection

GFP-expressing VSV (Whelan et al., 2000) was obtained from Dr. Sean Whelan and propagated by infecting Vero cells grown in cDMEM for 48 hours, after which infectious supernatant was harvested and cleared by centrifugation (1,000 X g for 10 minutes at 4°C) and frozen at -80°C prior to titering. To determine the titer of viral stocks, confluent Vero cells were inoculated with serial dilutions of VSV in serum-free DMEM for 2 hours, overlaid with cDMEM containing 2% SeaPlaque Agarose (Lonza), and incubated at 37°C for an additional 24 hours. Cells were then fixed using 4% formaldehyde and visualized to count GFP-expressing plaques and calculate plaque forming units/mL.

Microscopy to determine percent of cells infected by VSV

Experimental VSV infections were performed at a multiplicity of infection of 2 in serum-free DMEM for 1.5 h, after which cDMEM was replenished. Cells were fixed in 4% formaldehyde, washed with PBS, and stained for DAPI (4',6-diamidino-2-phenylindole) (Life Technologies, 1:1000). For each condition, 5 images were acquired at 10X magnification on a Zeiss Axio Observer Z1 microscope, and images were processed using ZEN 2 (Zeiss). The percent of cells infected was calculated by counting the number of GFP-positive cells / the number of nuclei (DAPI).

Flow Cytometry to determine percent of cells infected by VSV

Flow cytometry was performed as previously described (Alvarez et al., 2017). Briefly, VSV-infected cells were stained with 7-amino-actinomycin D (7-AAD) to separate live (7-AAD-negative) from dead (7-AAD-positive) cells, and the percent of cells infected was measured by quantifying the number of GFP-positive, 7-AAD-negative cells at 6 h post-infection.

Experimental Titration of VSV-infected supernatants

Supernatant harvested from experimental-treated cells infected by VSV was harvested at 6 h post-infection. Confluent cultures of naive Huh7.5 cells in 96-well plates were inoculated with serially-diluted supernatants in serum-free DMEM, and cDMEM was replenished 2 h post-infection. At 6 h post-infection, cells were fixed in 4% formaldehyde and visualized to count GFP-positive foci and calculate focus forming units/mL.

Plasmids

These plasmids have been described previously: pLEX-FLAG-YTHDF1 (Kennedy et al., 2016), psiCheck2-m⁶A null (Gokhale et al., 2019), psPAX2 (Addgene plasmid #12260; RRID:Addgene_12260), and pMD2.G (Addgene plasmid # 12259; RRID:Addgene_12259). The following plasmids were constructed in this study: pLEX-FLAG-METTL14, pLEX-FLAG-YTHDF1 W465A, and psiCheck2-m⁶A null-ISRE-*IFITM1* 3' UTR reporter (wild-type and m⁶A-mut). pLEX-FLAG-METTL14 was generated by cloning the PCR-amplified FLAG-tagged METTL14 coding sequence into the BamHI and XhoI restriction sites of the pLEX expression vector. pLEX-FLAG-YTHDF1

W465A was generated by site-directed mutagenesis of pLEX-FLAG-YTHDF1. WT and m⁶A-mut IFITM1 3' UTR reporter plasmids (psi-Check2-m⁶A null-ISRE-*IFITM1* 3' UTR reporter) were generated by inserting either wild-type *IFITM1* 3' UTR cDNA or *IFITM1* 3' UTR cDNA with 4 A-to-G mutations at potential m⁶A sites (obtained as IDT gBlocks) into the XhoI and NotI restriction sites of psiCheck2-m⁶A null (Gokhale et al., 2019). The 5X ISRE promoter was PCR-amplified from pISRE-luc (Sumpter et al., 2005) then inserted into the KpnI and NheI sites. All DNA sequences were verified by sequencing.

Transfection

siRNAs directed against METTL3 (SI04317096), METTL14 (SI00459942), or non-targeting AllStars negative control siRNA (1027280) were purchased from QIAGEN. All siRNA transfections were performed using the Lipofectamine RNAiMax reagent (Invitrogen), according to manufacturer's instructions. siMETTL3/14 co-transfections were performed at a ratio of 1:2 siMETTL3:siMETTL14. Huh7 and A549 cells were transfected with 25 pmol of siRNA at a final concentration of 0.0125 μ M, and NHDF cells were transfected with 250 pmol of siRNA at a final concentration of 0.25 μ M. Media was changed 4 hours post-transfection, and cells were incubated for 36 h post-transfection prior to each experimental treatment. Plasmid transfections of IFITM1 3' UTR reporter plasmids (500 ng per single well of a 6-well plate) were performed using the FuGENE 6 (Promega), according to manufacturer's instructions.

Generation of Overexpression Cell Lines

Lentiviral particles were generated by harvesting supernatant 72 h post-transfection of 293T cells with pLEX-FLAG-METTL14, pLEX-FLAG-YTHDF1, or pLEX-FLAG-YTHDF1 W465A, and the packaging plasmids psPAX2 and pMD2.G (provided by Duke Functional Genomics Facility). This supernatant was then used to transduce Huh7 cells for 48 hours. Following transduction, cells were selected in 2 μ g/mL puromycin (Sigma) for 48 hours and then single cell colonies were isolated. Overexpression of FLAG-tagged proteins in selected colonies was verified by immunoblotting, and we also verified that METTL14 overexpression stabilized METTL3 (Ping et al., 2014), creating METTL3/14 overexpression cell lines. These clones were maintained in cDMEM containing 1 μ g/mL puromycin.

Immunoblotting

Cells were lysed in a modified radioimmunoprecipitation assay (RIPA) buffer (10 mM Tris [pH 7.5], 150 mM NaCl, 0.5% sodium deoxycholate, and 1% Triton X-100) supplemented with protease inhibitor cocktail (Sigma) and phosphatase inhibitor cocktail II (Millipore), and post-nuclear lysates were harvested by centrifugation. Quantified protein (between 5 and 15 μ g) was added to a 4X SDS protein sample buffer (40% glycerol, 240 mM Tris-HCl [pH 6.8], 8% SDS, 0.04% bromophenol blue, 5% beta-mercaptoethanol), resolved by SDS/PAGE, and transferred to nitrocellulose membranes in a 25 mM Tris-192 mM glycine-0.01% SDS buffer. Membranes were stained with Revert 700 total protein stain (LI-COR Biosciences), then blocked in 3% bovine serum albumin. Membranes were incubated with primary antibodies for 2 hours at room temperature or overnight at 4°C. After washing with PBS-T buffer (1 \times PBS, 0.05% Tween 20), membranes were incubated with species-specific horseradish peroxidase-conjugated antibodies (Jackson ImmunoResearch, 1:5000) for 1 hour at room temperature, followed by treatment of the membrane with Clarity enhanced chemiluminescence (Bio-Rad) and imaging on an Odyssey Fc imaging system (LI-COR Biosciences). The following antibodies were used for immunoblotting: mouse anti-IFITM1 (Proteintech 60074-1-Ig, 1:1000; recognizes IFITM1 but not IFITM2 or IFITM3; Shi et al., 2018; Xie et al., 2015), rabbit anti-MX1 (Abcam ab207414, 1:1000), mouse anti-ISG15 (Santa Cruz sc-166755, 1:5000), rabbit anti-EIF2AK2 (Abcam ab32506, 1:1000), rabbit anti-METTL14 (Sigma HPA038002, 1:2500), mouse anti-METTL3 (Abnova H00056339-B01P, 1:1000), rabbit anti-YTHDF1 (Proteintech 17479-1-AP, 1:1000), mouse anti-FLAG-HRP (Sigma A8592, 1:5000), rabbit anti-GFP (Thermo Fisher Scientific A-11122, 1:1000).

Quantification of Immunoblots

Following imaging using the LI-COR Odyssey Fc, immunoblots were quantified using ImageStudio Lite software, and raw values were normalized to total protein (Revert 700 total protein stain) for each condition.

MeRIP-seq

Following mock or IFN- β treatment of Huh7 cells for 8 hours, cellular RNA was harvested using TRIzol (Thermo Fisher Scientific), polyA-tailed mRNA was selected using the Dynabeads mRNA Purification kit (Thermo Fisher Scientific), and MeRIP-seq was performed using the NEB EpiMark m⁶A-enrichment kit as previously described (Gokhale et al., 2019) with the following modifications. Briefly, 25 mL Protein G Dynabeads (Thermo Fisher) per sample were washed three times in MeRIP buffer (150 mM NaCl, 10 mM Tris-HCl [pH 7.5], 0.1% NP-40), and incubated with 1 mL anti-m⁶A antibody for 2 h at 4°C with rotation. After washing three times with MeRIP buffer, anti-m⁶A conjugated beads were incubated with purified mRNA with rotation at 4°C overnight in 300 mL MeRIP buffer with 1 mL RNase inhibitor (recombinant RNasin; Promega). 10% of the mRNA sample was saved as the input fraction. Beads were then washed twice with 500 mL MeRIP buffer, twice with low salt wash buffer (50 mM NaCl, 10 mM Tris-HCl [pH 7.5], 0.1% NP-40), twice with high salt wash buffer (500 mM NaCl, 10 mM Tris-HCl [pH 7.5], 0.1% NP-40), and once again with MeRIP buffer. m⁶A-modified RNA was eluted twice in 100 mL of MeRIP buffer containing 5 mM m⁶A salt (Santa Cruz Biotechnology) for 30 min at 4°C with rotation. Eluates were pooled and concentrated by ethanol purification. RNA-seq libraries were prepared from both eluate and 10% input mRNA using the TruSeq mRNA library prep kit (Illumina), subjected to quality control (MultiQC), and sequenced on the HiSeq 4000 instrument.

RT-qPCR

Total cellular RNA was extracted using the QIAGEN RNeasy kit (Life Technologies) or TRIzol extraction (Thermo Fisher Scientific). RNA was then reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad) as per the manufacturer's instructions. The resulting cDNA was diluted 1:5 in nuclease-free H₂O. RT-qPCR was performed in triplicate using the Power SYBR Green PCR master mix (Thermo Fisher Scientific) and the Applied Biosystems Step One Plus or QuantStudio 6 Flex RT-PCR systems. The oligonucleotide sequences used are listed in [Data S5](#).

Nuclear/Cytoplasmic Fractionation

Following siRNA treatment (36 h) and IFN- β treatment (20 h), cells were harvested and lysed in 200 μ L lysis buffer (10 mM Tris-HCl [pH 7.4], 140 mM NaCl, 1.5 mM MgCl₂, 10 mM EDTA, 0.5% Nonidet P-40 (NP-40)) on ice for 10 minutes. Following centrifugation at 12000 X g at 4°C for 5 minutes, the supernatant (cytoplasmic fraction) was collected, and the nuclear pellet was rinsed twice with lysis buffer. RNA was extracted from cytoplasmic and nuclear pellets using TRIzol reagent and analyzed by RT-qPCR.

Protein Stability Analysis

Following siRNA treatment (36 h), Huh7 cells were treated with IFN- β for 16 hours to induce ISGs. IFN- β was then replenished at half the dose in cDMEM containing either DMSO as a control, or 50 μ g/mL cycloheximide (CHX, Sigma-Aldrich). Cells were harvested over a time course (0, 2, 4, 6, 8, 12 hours post-CHX) and subjected to immunoblotting. Protein stability was determined by measuring the protein remaining at each time point following CHX treatment.

Polysome Profiling

Cells treated with siRNAs (36 h) were treated with IFN- β for 6 hours, then pulsed with CHX (50 μ g/mL) for 10 minutes. Cells were harvested using trypsin and then lysed in cytoplasmic lysis buffer (200 mM KCl, 25 mM HEPES [pH 7.0], 10 mM MgCl₂, 2% n-Dodecyl β -D-maltoside (DDM; Chem-Impex), 0.2 mM CHX, 1 mM DTT, 40 U RNasin) for 15 minutes on ice. Following clarification, lysates were ultracentrifuged on 15%–50% sucrose gradients prepared in polysome gradient buffer (200 mM KCl, 25 mM HEPES [pH 7.0], 15 mM MgCl₂, 1 mM DTT, 0.2 mM CHX) at 35,000 X g for 3.5 hours at 4°C. Following ultracentrifugation, 24 fractions were collected from each sample using a BioComp Piston Gradient Fractionator instrument fitted with a TRIAX flow cell to measure absorbance. RNA was extracted from each fraction using TRIzol LS reagent (Thermo Fisher Scientific), and RNA quality was checked on a 1% agarose gel. Following cDNA synthesis using the iScript cDNA synthesis kit (Bio-Rad), RT-qPCR was performed using primers specific for each gene.

MeRIP-RT-qPCR

Total cellular RNA was harvested using TRIzol reagent and normalized to equal input concentrations. m⁶A-positive and m⁶A-negative control oligonucleotides (EpiMark N6-Methyladenosine Enrichment Kit, New England Biolabs) were spiked into total RNA prior to immunoprecipitation. RNA was then immunoprecipitated with anti-m⁶A antibody (New England Biolabs) overnight at 4°C with head-over-tail rotation, and then washed twice with 1X reaction buffer (150mM NaCl, 10mM Tris-HCl, pH 7.5, 0.1% NP40), twice with low salt wash buffer (50 mM NaCl, 10 mM Tris-HCl, pH 7.5, 0.1% NP-40), twice with high salt wash buffer (500 mM NaCl, 10 mM Tris-HCl, pH 7.5, 0.1% NP-40), and once with 1X reaction buffer. RNA was eluted from beads in elution buffer twice for 1 hour at 4°C, and then precipitated in isopropanol overnight at –20°C, pelleted by centrifugation, and resuspended in nuclease-free water. Equal volumes of eluted RNA and input RNA were used for cDNA synthesis and quantified by RT-qPCR. IP efficiency was normalized by relative pulldown of spike-in positive controls.

Luciferase Assays

Following plasmid transfection of WT and m⁶A-mut IFITM1 3' UTR reporters and mock or IFN- β treatment (12 h), a dual luciferase assay (Promega) was performed according to manufacturer's instructions. Data was normalized as fold-change (IFN- β over mock) of the value of *Renilla* luminescence divided by firefly luminescence, and values for WT IFITM1 3' UTR reporter were set as 1.

RNA Immunoprecipitation

Following DNA transfection (16 h) and IFN- β treatment (8 h), cells were harvested and lysed in polysome lysis buffer (100 mM KCl, 5 mM MgCl₂, 10 mM HEPES [pH 7.0], 0.5% NP-40) supplemented with protease inhibitor cocktail (Sigma) and RNasin ribonuclease inhibitor (Promega), and lysates were cleared by centrifugation. Ribonucleoprotein complexes were immunoprecipitated with anti-FLAG M2 beads (Sigma) overnight at 4°C with head-over-tail rotation, and then washed five times in ice-cold NT2 buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM MgCl₂, 0.05% NP-40). Protein for immunoblotting was eluted from 25 percent of beads by boiling in 2X Laemmli sample buffer (Bio-Rad). RNA was extracted from 75 percent of beads using TRIzol reagent (Thermo Fisher Scientific). Equal volumes of eluted RNA were used for cDNA synthesis, quantified by RT-qPCR, and normalized to RNA levels in input samples. Enrichment over GFP was then calculated and plotted.

RNA-seq

Following siRNA treatment (36 h), Huh7 cells seeded in 10-cm² plates were stimulated with IFN- β or mock treated (8 h), then harvested and RNA extraction was performed using TRIzol reagent (Thermo Fisher Scientific). Samples were then treated with Turbo

DNase I (Thermo Fisher Scientific) according to manufacturer protocol and incubated at 37°C for 30 min, followed by phenol/chloroform extraction and ethanol precipitation overnight. RNA concentrations were then normalized. Sequencing libraries were prepared using the KAPA Stranded mRNA-Seq Kit (Roche) and sequenced on an Illumina HiSeq 4000 with 100 bp paired-end reads by the Duke University Center for Genomic and Computational Biology.

Ribo-seq

Following siRNA treatment (36 h), Huh7 cells seeded in 15-cm² plates were stimulated with IFN-β (8 h), then washed with ice cold PBS, and flash frozen in liquid nitrogen. Cells were then lysed in plates with polysome lysis buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 5 mM MgCl₂, 1 mM DTT, 1% Triton X-100, 25 U/mL Turbo DNase I (Thermo Fisher Scientific)), scraped, and passed through a 25 gauge needle before collection in microfuge tubes and incubation for 15 minutes on ice. Cytoplasmic lysates were clarified by centrifugation. 5% of lysate was taken for western blotting, and the remaining cytoplasmic lysate was supplemented with 0.4M CaCl₂ and 4000 gel units micrococcal nuclease (New England Biolabs), and incubated at 37°C (30 min) to generate ribosome protected fragments (RPF RNA). RPF RNA was then ultracentrifuged (35000 X g at 4°C for 3.5 h), over 15%–50% sucrose gradients in polysome gradient buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 5 mM MgCl₂, 1 mM DTT), after which 12 fractions were collected from each sample using a BioComp Piston Gradient Fractionator instrument fitted with a TRIAX flow cell to measure absorbance. Monosome fractions (fractions 6 and 7) were then pooled and loaded onto a 100 kD molecular weight cut-off filter (Vivaspin 20) and centrifuged at 3000 X g at 4°C for 35 minutes to concentrate monosome-bound RPF RNA. The flow-through was discarded and retained monosomes were separated from RPF RNA by adding polysome lysis buffer supplemented with 50 mM EDTA and incubation on ice for 15 minutes. The resulting RPF RNA solution was then re-applied to the emptied 100 kD molecular weight cut-off filter and centrifuged at 3000 X g at 4°C for 15 minutes to separate RPF RNA from monosomes. The flow-through containing the RPF RNA was then collected, phenol-chloroform extracted, and ethanol precipitated. Precipitated RPF RNA samples were then run on a 15% TBE-Urea gel (Invitrogen), and a band corresponding to 28–32 nucleotides was excised, crushed, and incubated in 0.4M NaCl with 40 units of RNasin ribonuclease inhibitor (Promega) for 8 hours shaking at 4°C 1100 RPM. RNA was recovered by filtration through Corning Costar Spin-X columns (Sigma-Aldrich) then isopropanol precipitated overnight. After resuspension, the remaining RNA was T4 Polynucleotide Kinase (New England Biolabs) treated, phenol-chloroform extracted, and precipitated in ethanol overnight. Sequencing libraries for RPF samples were then generated using the NEB Next small RNA library prep kit and these libraries were sequenced on an Illumina NextSeq 500 High-output 75 bp with paired end reads by the Duke University Center for Genomic and Computational Biology.

Mass Spectrometry

Prior to the siRNA experiments, cells were grown for at least 12 generations in DMEM medium without Lysine and Arginine (#PI88420), supplemented with Dialyzed FBS (#26000044), either light or heavy L-Arginine and L-Lysine (L-Arginine-HCl #PI88427; L-Arginine-HCl, 13C6, 15N4 #PI88434; L-Lysine-2HCl #PI88429; L-Lysine-2HCl, 13C6, 15N2 #PI88432), and 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine. Following stable isotope labeling, siRNA-treated cells (36 h) were stimulated with IFN-β for 24 hours prior to harvest by trypsinization and lysis in RIPA buffer supplemented with protease inhibitor cocktail (Sigma) and phosphatase inhibitor cocktail II (Millipore), and post-nuclear lysates were harvested by centrifugation. 5 μL at 1 μg/μL of siMETTL3/14 (Heavy) extracts were mixed with 5 μL at 1 μg/μL of siCTRL (Light) extracts for the Forward experiment, and 5 μL at 1 μg/μL of siMETTL3/14 (Light) extracts were mixed with 5 μL at 1 μg/μL of siCTRL (Heavy) extracts for the Reverse experiment. The lysates were run on a 4%–12% Bis-Tris gel for 30 min. The gel was stained with Colloidal Coomassie and a single patch was cut and processed for each sample. The gel patches were digested with trypsin. The resulting peptides were cleaned with a C18 tip. Liquid chromatography was performed with an EASY-nLC 1000 Integrated Ultra High Pressure Nano-HPLC System and MS/MS with a Q-EXACTIVE System equipped with a Nanospray Flex Ion Source, as previously described (Abell et al., 2017).

QUANTIFICATION AND STATISTICAL ANALYSIS

Western blot images were acquired and analyzed using Li-Cor Image Studio. Figure panels were processed and organized using Adobe Illustrator CC. qRT-PCR and MeRIP-qRT-PCR data was analyzed using Microsoft Excel. Graphpad Prism 8 was used to generate graphs, to determine the mean, standard deviation or standard error, and to perform statistical analyses. This information, as well as the number of replicates performed for each experiment, are stated in the figure legends.

MeRIP-seq Data Analysis

Reads were trimmed using Trimmomatic (Bolger et al., 2014) and aligned to the hg38 genome using the splice-aware STAR aligner (Dobin et al., 2013). Changes in gene expression between Mock and IFN-β treated samples were then identified using DESeq2 (Love et al., 2014) based on differences in read counts from featureCounts (Liao et al., 2014) and plotted in Figure S2A. m⁶A peaks were identified in IFN-β treated samples using the MeTDiff peak caller (Cui et al., 2018) and with meRIPper (<https://sourceforge.net/projects/meripper/>). Presented data are from MeTDiff analysis unless otherwise noted. Raw data from Winkler et al. (2019) and Rubio et al., (2018) were similarly processed (Figure S2B). Coverage plots were generated using CovFuzze (Imam et al., 2018) and a meta-gene plot for peak locations produced as previously described (Gokhale et al., 2019). Motif enrichment was calculated using HOMER

(Heinz et al., 2010). Full methods and scripts for data processing are open-source and online on GitHub (https://github.com/al-mcintyre/merip_reanalysis_scripts) (McIntyre et al., 2020).

RNA-seq and Ribo-seq Data Analysis

Reads were evaluated using FastQC and trimmed using cutadapt (Martin, 2011), followed by alignment to the hg38 human reference genome using the STAR aligner with default parameters. The number of read fragments uniquely aligned to each gene were counted with the Gencode v21 main comprehensive gene annotation file (aggregated by gene_name) using featureCounts. Using a python script, the raw counts from each replicate and condition were merged to generate a count matrix with N rows/genes and M samples/columns (python scripts for count-matrix generation are open-source and online on GitHub; https://github.com/hmourelatos/McFadden_ISG_m6a_countMatrices). To identify differentially expressed genes between various groups, we used DESeq2 (Love et al., 2014) to perform three pairwise contrasts. First, with RNA-seq we compared the effects of IFN- β and mock treatment in cells transfected with siCTRL (Data S1.1). Additional RNA-seq analyses included comparison of siMETTL3/14 and siCTRL treated cells after both IFN- β and mock treatment (Data S1.2 and S1.3, respectively). Finally, with Ribo-seq, we compared siMETTL3/14 and siCTRL treated cells following IFN- β treatment (Data S4). In each case, DESeq2 was applied with no additional covariates and results shown in Data S1.1, S1.2, and S3 respectively. Metagene plots from Ribo-seq reads were composed using deepTools v3.1 (Ramírez et al., 2016) with the computeMatrix utility. RNA-seq heatmap was generated using R software, and the heatmap for Ribo-seq was generated using ClustVis (Metsalu and Vilo, 2015).

Mass Spectrometry Data Analysis

Four RAW files representing two replicates each of Forward and Reverse SILAC experiments were retrieved from the Orbitrap. Heavy/light label ratios were quantified across all samples using MaxQuant v1.6.7.0 with the Andromeda search engine and default parameters other than specifying SILAC labels (Cox and Mann, 2008; Cox et al., 2011). For all analyses, the “H/L Ratio – Normalized” field containing median-centered label ratios was extracted for each peptide and/or protein and compared across replicates (Data S3). Heatmaps for mass spectrometry were generated using ClustVis (Metsalu and Vilo, 2015).

Peptide regression modeling

To take advantage of the measurement independence of unique peptides, we applied a simple linear mixed model to identify significant shifts in labeling ratio between conditions while accounting for peptide-specific effects. First, we merge all proteins that are described by the same set of peptide ratios (e.g., protein sequences from the same gene for which all detected peptides are shared). Then, for each protein (defined now as a set of peptide ratios), we fit a linear model of the following form using lme4 in R (Bates et al., 2015)

$$r \sim Z u_{\text{pep}} + X \beta_{\text{label}} + \varepsilon$$

where:

- r is the median-normalized heavy/light label ratio derived from MaxQuant
- Z is a binary design matrix indicating the peptide identity of each ratio measurement
- X is a binary design vector indicating condition (forward or reverse)
- u_{pep} is a vector of random effects corresponding to each peptide effect
- β_{label} is the fixed effect of condition

Thus, each peptide ratio is described as the sum of a peptide-level random effect and a condition (forward versus reverse) fixed effect, and some error. We extract effect size estimates and p values from unmodified Wald tests on the fixed effect of condition, and adjust across all proteins with the Benjamini-Hochberg (BH) procedure. Note that in the less-powerful case of proteins with only one measured peptide, the random peptide effect is just a constant and the model reduces to simply comparing the means of the forward and reverse replicate ratios for the single peptide.

Aggregating proteins for gene-level results:

Peptide regression modeling generates one test for each protein, so many genes are tested multiple times at each of their proteins. Annotated reference protein sequences often contain multiple entries per gene with varying degrees of similarity. After applying the procedure above, we observe as expected that the vast majority of genes contain either all significant or all non-significant protein results. We conservatively describe as significant any gene with a significant maximum p value (meaning all tested proteins are significant) following multiple test correction.